Case: 1:17-md-02804-DAP Doc #: 1225 Filed: 01/04/19 1 of 5. PageID #: 29636 UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF OHIO EASTERN DIVISION MDL No. 2804 IN RE: NATIONAL PRESCRIPTION OPIATE LITIGATION Case No. 1:17-md-2804 THIS DOCUMENT RELATES TO: ALL CASES Hon. Dan Aaron Polster CERTAIN DEFENDANTS’ MOTION FOR LEAVE TO FILE MOTION FOR RELIEF CONCERNING IMPROPER EXTRAJUDICIAL STATEMENTS AND VIOLATIONS OF COURT ORDERS The undersigned Defendants move this Court for leave to file the annexed Motion for Relief Concerning Improper Extrajudicial Statements and Violation of Court Orders and memorandum in support thereof. Lawyers representing plaintiffs in this litigation are engaged in a concerted campaign to taint potential jury pools in this district—and across the country—through misleading, inflammatory, and improper public statements. Their behavior, which reached a crescendo on national TV during a recent episode of 60 Minutes, is a flagrant violation of their ethical obligations as attorneys practicing before this Court and threatens defendants’ rights to a fair adjudication of the claims asserted against them. Certain statements by plaintiffs’ counsel also have violated this Court’s express orders. These lawyers’ professional misconduct is so far outside the bounds of appropriate behavior as to warrant a gag order and other sanctions. Such steps are necessary to help mitigate the unfair and prejudicial effects of the misconduct and to deter similar misconduct in the future. The essential fairness of this proceeding and the rights of the parties are at stake. 1 Case: 1:17-md-02804-DAP Doc #: 1225 Filed: 01/04/19 2 of 5. PageID #: 29637 For these reasons and those more fully set forth in the annexed motion and memorandum in support, the Court should grant Defendants leave to file the annexed Motion for Relief Concerning Improper Extrajudicial Statements and Violation of Court Orders and memorandum in support thereof. January 4, 2019 Respectfully submitted, /s/ Carole S. Rendon Carole S. Rendon BAKER & HOSTETLER LLP Key Tower 127 Public Square, Suite 2000 Cleveland, OH 44114-1214 Tel: (216) 621- 0200 Fax: (216) 696-0740 crendon@bakerlaw.com Counsel for Defendants Endo Health Solutions Inc., Endo Pharmaceuticals Inc., Par Pharmaceutical, Inc., and Par Pharmaceutical Companies, Inc. (incorrectly named as “Par Pharmaceutical Companies, Inc. f/k/a Par Pharmaceutical Holdings, Inc.”) /s/ Donna M. Welch Donna M. Welch, P.C. (Illinois Bar No. 6226352) KIRKLAND & ELLIS LLP 300 North LaSalle Chicago, Illinois 60654 Tel: (312) 862-2424 Fax: (312) 862-2200 dwelch@kirkland.com Counsel for Defendants Allergan Finance, LLC f/k/a Actavis, Inc. f/k/a Watson Pharmaceuticals, Inc. and Allergan PLC f/k/a Actavis PLC 2 Case: 1:17-md-02804-DAP Doc #: 1225 Filed: 01/04/19 3 of 5. PageID #: 29638 /s/ Shannon McClure Roberts Shannon McClure Roberts REED SMITH LLP Three Logan Square 1717 Arch Street, Suite 3100 Philadelphia, PA 19103 Tel: (215) 851-8100 Fax: (215) 851-1420 smcclure@reedsmith.com Counsel for Distributor Defendant AmerisourceBergen Drug Corporation Counsel for H.D. Smith for the limited purpose of this motion /s/ Enu Mainigi Enu Mainigi WILLIAMS & CONNOLLY LLP 725 Twelfth Street, N.W. Washington, DC 20005 Tel: (202) 434-5000 Fax: (202) 434-5029 emainigi@wc.com Counsel for Defendant Cardinal Health, Inc. /s/ Timothy D. Johnson Timothy D. Johnson (0006686) CAVITCH, FAMILO & DURKIN CO. LPA Twentieth Floor 1300 East Ninth Street Cleveland, Ohio 44114 Tel: (216) 621-7860 Fax: (216) 621-3415 tjohnson@cavitch.com Attorney for Discount Drug Mart, Inc. 3 Case: 1:17-md-02804-DAP Doc #: 1225 Filed: 01/04/19 4 of 5. PageID #: 29639 /s/ Charles C. Lifland Charles C. Lifland (Cal. Bar No. 108950) O’MELVENY & MYERS LLP 400 South Hope Street Los Angeles, California 90071 Tel: (213) 430-6000 Fax: (213) 430-6407 clifland@omm.com Counsel for Defendants Johnson & Johnson; Janssen Pharmaceuticals, Inc.; Janssen Pharmaceutica, Inc. n/k/a Janssen Pharmaceuticals, Inc.; and OrthoMcNeil-Janssen Pharmaceuticals, Inc. n/k/a Janssen Pharmaceuticals, Inc. /s/ Brien T. O’Connor Brien T. O’Connor Andrew J. O’Connor ROPES & GRAY LLP Prudential Tower 800 Boylston St. Boston, MA 02199 Tel: (617) 235-4650 Brien.O’Connor@ropesgray.com Andrew.O’Connor@ropesgray.com Counsel for Defendant Mallinckrodt LLC /s/ Geoffrey Hobart Geoffrey Hobart COVINGTON & BURLING LLP One CityCenter 850 Tenth Street, NW Washington, DC 20001-4956 Tel: (202) 662-5281 ghobart@cov.com Counsel for Distributor Defendant McKesson Corporation 4 Case: 1:17-md-02804-DAP Doc #: 1225 Filed: 01/04/19 5 of 5. PageID #: 29640 /s/ Mark S. Cheffo Mark S. Cheffo DECHERT LLP Three Bryant Park 1095 Avenue of the Americas New York, NY 10036 Tel: (212) 698-3500 Mark.Cheffo@dechert.com Counsel for Defendants Purdue Pharma L.P., Purdue Pharma Inc., and The Purdue Frederick Company 5 Case: 1:17-md-02804-DAP Doc #: 1225-1 Filed: 01/04/19 1 of 5. PageID #: 29641 UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF OHIO EASTERN DIVISION IN RE: NATIONAL PRESCRIPTION OPIATE LITIGATION MDL No. 2804 Case No. 1:17-md-2804 THIS DOCUMENT RELATES TO: ALL CASES Hon. Dan Aaron Polster CERTAIN DEFENDANTS’ MOTION FOR RELIEF CONCERNING IMPROPER EXTRAJUDICIAL STATEMENTS AND VIOLATIONS OF COURT ORDERS The undersigned Defendants move this Court for the following relief and all other relief the Court deems necessary: (1) Mr. Moore, Mr. DeWine, and Mr. LeBlanc, all counsel representing the plaintiffs in this MDL, and all those who have received information or documents pursuant to this Court’s Orders, shall strictly comply with Rule 3.6 of the Ohio Rules of Professional Conduct and shall refrain from making any statements to the media or the public relating to any of the following subjects: (a) the character, credibility, or reputation of a party; (b) the strengths or weaknesses of any party’s case; (c) any information the attorneys know or reasonably should know is likely to be inadmissible evidence and would create a substantial risk of prejudice if disclosed; and (d) the ARCOS data or any information produced in discovery in this action. (2) Mr. Moore, Mr. DeWine, and Mr. LeBlanc shall be admonished for violating this Court’s orders and the Court should impose appropriate sanctions to deter future violations. (3) Mr. Moore, Mr. DeWine, and Mr. LeBlanc shall pay the defendants’ attorneys’ fees and costs incurred as a result of their misconduct. Case: 1:17-md-02804-DAP Doc #: 1225-1 Filed: 01/04/19 2 of 5. PageID #: 29642 (4) Pursuant to Local Rule 83.7(d)(1), this matter shall be referred to the Court’s Committee on Complaints and Policy Compliance, with notification to the Clerk of Court, for investigation and the prosecution of a formal disciplinary proceeding or the formulation of such other recommendation as is appropriate. (5) Mr. Moore, Mr. DeWine, and Mr. LeBlanc shall identify all counsel who were present for the taping of the 60 Minutes segment or otherwise knowingly assisted, induced, or participated in the effort in any way. This motion is supported by the attached Memorandum in Support of Motion for Relief Concerning Improper Extrajudicial Statements and Violations of Court Orders. January 4, 2019 Respectfully submitted, /s/ Carole S. Rendon Carole S. Rendon BAKER & HOSTETLER LLP Key Tower 127 Public Square, Suite 2000 Cleveland, OH 44114-1214 Tel: (216) 621- 0200 Fax: (216) 696-0740 crendon@bakerlaw.com Counsel for Defendants Endo Health Solutions Inc., Endo Pharmaceuticals Inc., Par Pharmaceutical, Inc., and Par Pharmaceutical Companies, Inc. (incorrectly named as “Par Pharmaceutical Companies, Inc. f/k/a Par Pharmaceutical Holdings, Inc.”) 2 Case: 1:17-md-02804-DAP Doc #: 1225-1 Filed: 01/04/19 3 of 5. PageID #: 29643 /s/ Donna M. Welch Donna M. Welch, P.C. (Illinois Bar No. 6226352) KIRKLAND & ELLIS LLP 300 North LaSalle Chicago, Illinois 60654 Tel: (312) 862-2424 Fax: (312) 862-2200 dwelch@kirkland.com Counsel for Defendants Allergan Finance, LLC f/k/a Actavis, Inc. f/k/a Watson Pharmaceuticals, Inc. and Allergan PLC f/k/a Actavis PLC /s/ Shannon McClure Roberts Shannon McClure Roberts REED SMITH LLP Three Logan Square 1717 Arch Street, Suite 3100 Philadelphia, PA 19103 Tel: (215) 851-8100 Fax: (215) 851-1420 smcclure@reedsmith.com Counsel for Distributor Defendant AmerisourceBergen Drug Corporation Counsel for H.D. Smith for the limited purpose of this motion /s/ Enu Mainigi Enu Mainigi WILLIAMS & CONNOLLY LLP 725 Twelfth Street, N.W. Washington, DC 20005 Tel: (202) 434-5000 Fax: (202) 434-5029 emainigi@wc.com Counsel for Defendant Cardinal Health, Inc. 3 Case: 1:17-md-02804-DAP Doc #: 1225-1 Filed: 01/04/19 4 of 5. PageID #: 29644 /s/ Timothy D. Johnson Timothy D. Johnson (0006686) CAVITCH, FAMILO & DURKIN CO. LPA Twentieth Floor 1300 East Ninth Street Cleveland, Ohio 44114 Tel: (216) 621-7860 Fax: (216) 621-3415 tjohnson@cavitch.com Attorney for Discount Drug Mart, Inc. /s/ Charles C. Lifland Charles C. Lifland (Cal. Bar No. 108950) O’MELVENY & MYERS LLP 400 South Hope Street Los Angeles, California 90071 Tel: (213) 430-6000 Fax: (213) 430-6407 clifland@omm.com Counsel for Defendants Johnson & Johnson; Janssen Pharmaceuticals, Inc.; Janssen Pharmaceutica, Inc. n/k/a Janssen Pharmaceuticals, Inc.; and OrthoMcNeil-Janssen Pharmaceuticals, Inc. n/k/a Janssen Pharmaceuticals, Inc. /s/ Brien T. O’Connor Brien T. O’Connor Andrew J. O’Connor ROPES & GRAY LLP Prudential Tower 800 Boylston St. Boston, MA 02199 Tel: (617) 235-4650 Brien.O’Connor@ropesgray.com Andrew.O’Connor@ropesgray.com Counsel for Defendant Mallinckrodt LLC 4 Case: 1:17-md-02804-DAP Doc #: 1225-1 Filed: 01/04/19 5 of 5. PageID #: 29645 /s/ Geoffrey Hobart Geoffrey Hobart COVINGTON & BURLING LLP One CityCenter 850 Tenth Street, NW Washington, DC 20001-4956 Tel: (202) 662-5281 ghobart@cov.com Counsel for Distributor Defendant McKesson Corporation /s/ Mark S. Cheffo Mark S. Cheffo DECHERT LLP Three Bryant Park 1095 Avenue of the Americas New York, NY 10036 Tel: (212) 698-3500 Mark.Cheffo@dechert.com Counsel for Defendants Purdue Pharma L.P., Purdue Pharma Inc., and The Purdue Frederick Company 5 Case: 1:17-md-02804-DAP Doc #: 1225-2 Filed: 01/04/19 1 of 26. PageID #: 29646 01234567383476527392 36 0936 1 93 4916527392 36 6 2 6 4873491652 272 1666 21694 61832 18 6 947 92 32 16 28346 232 832 16 ! " ! ! #$%&'()&*+,-& ./01&'()&23245675*+,-& 8(9)&$/9&:/;(9&<(=0>1;& 493821654 4158137?66 @4@ 98150@621670 936 6@ 32 16 9694 24 66 1 49121 62@ 9 4964A398B052 28 673834@413766 8156 2 832 176 6 0936 954976 Case: 1:17-md-02804-DAP Doc #: 1225-2 Filed: 01/04/19 2 of 26. PageID #: 29647 38D 46 6 1341376 EFG H'IJK$L.IHK'&)))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))2 M:.IL:%&N:.OPJKL'$&))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))2 :JPL#Q'I&)))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))R H) <%:H'IHMMST&.KL'SQ%&UHK%:IQ$&I8Q&K8HK&JL%QS&KM& &SX(Y=7&H00Y1&/&P/Z&K;71;&#/97/>C9Z&S>;C[>&.(6\=C/9[1&]C>X& KXC(&JY=1&(^&<;(^100C(9/=&.(97Y[>&_)R)&))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))2* N) IXC0&.(Y;>&SX(Y=7&K;71;&J1=C1^&M(;&<=/C9>C^^0T&.(Y901=T0&UC(=/>C(90&(^&H>0& <;1`C(Y0&K;71;0)&)))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))2.) IXC0&.(Y;>&SX(Y=7&:]/;7&$1^197/9>0&IX1C;&:>>(;91a0T&M110&/97&.(0>0& H9[Y;;17&:0&:&J10Y=>&K^&<=/C9>C^^0T&.(Y901=T0&#C0[(97Y[>)&)))))))))))))))))))))))))))))))))2R $) IXC0&.(Y;>&#Y0>&J1^1;&:==1Z/>C(90&(^&<;(^100C(9/=&#C0[(97Y[>&>(&>X1& .(Y;>T0&.(66C>>11&(9&.(6\=/C9>0&/97&<(=C[a&.(6\=C/9[1)&)))))))))))))))))))))))))))))))))2R .K'.%LSHK'&))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))24 C& Case: 1:17-md-02804-DAP Doc #: 1225-2 Filed: 01/04/19 3 of 26. PageID #: 29648 38D 46 6803 9232476 87476 6 EFGbcd6 efghijkljmnggfiop& '()&232_5[`5*,*p&*,2_&W%&2*2*2q2R&rS)$)&KXC(&K[>)&2p&*,2_s&))))))))))))))))))))))))))))))))))+p&2*p&2_& eituhivjwljxfitofyjzz{jklj }~ftj€~hgtyj ilp& '()&_3,V5[`5_R*p&*,22&W%&2_*_*-++&rS)$)&KXC(&'(`)&+p&*,22s&)))))))))))))))))))))))))))))))))))))))))))))4& ‚ghƒijklj„…††…g}ft…j‡h†ˆoi‰jztˆlp& '()&*3225[`522**p&*,2q&W%&-4-*R+R&rS)$)&KXC(&:YZ)&22p&*,2qs&)))))))))))))))))))))))))))))))))))2qp&2R& mh…jkljŠh…p& '()&.U52q5,4q,_p&*,2R&W%&V2,42_4&r.)$)&./=)&S1\>)&_,p&*,2Rs&)))))))))))))))))))))))))))))))))4p&+p&2-& mhg…ttjklj{hnitvjh‹jŒffnp& '()&.U&2,5,2*q+&:$Sp&*,2*&W%&*,4RV22&rQ)$)'))&ŽY91&4p&*,2*s&)))))))))))))))))))))))))))))))))))2-& o…†ˆj„ng‹j€eyj iljklj€~hgtj{hitlj‘ghn~yjzz{p& '()&23,R&.U&*R*-p&*,,4&W%&--2*+qq&r')$)&KXC(&$1[)&2*p&*,,4s&))))))))))))))))))))))))))))))))))))))))2q& ‘…ito†…jklj€tft…j‚fgjh‹jŒ…kfˆfp& q,2&L)S)&2,_,&r2VV2s&)))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))Rp&4p&2_& ‘hhˆv…fgj„og…j’jŠn““…gj{hljklj‡f…‰…gp& 2_4&S)&.>)&224+&r*,24s&)))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))2R& ”ih•jklj{otvjh‹jg…ihp& '()&232-5[`5,,4VVp&*,2R&W%&2,R-42V+&rQ)$)&./=)&ŽY91&*p&*,2Rs&)))))))))))))))))))))))))))))))))))))))))2q& xfiijkljiokljh‹j{oioiiftop& +*-&M)&SY\\)&22V,&rS)$)&KXC(&2VV_sp&f‹‹–ˆy&2q*&M)J)$)&22V&rS)$)&KXC(&2VV_sp& f‹‹–ˆp&22-&M)_7&22++&rR>X&.C;)&2VV4s&))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))2q& xmhif†ˆjklj{hh~…gj„og…j’jŠn““…gj{hlp& '()&+3,25[`52_,Rp&*,,q&W%&*+2,4,4&r#)$)&M=/)&K[>)&*4p&*,,qs&)))))))))))))))))))))))))))))))))))))))))))2q& Œft–†j‡h—…vjz…f‰n…jkljx…tlj‡h—…vj{†n“p& -*4&L)S)&R_V&r2V4Rs&)))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))2*& ˜fn†…vjkljiot…ˆj™~…gftoi‰j{hlp& R,R&M)&SY\\)&q*,&rQ)$)&#C[X)&2V+qs&))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))2*& €}otuj’jn††…gyj˜leljklj{hh~…gj„og…j’jŠn““…gj{hlp& R+q&M)_7&-+R&rq>X&.C;)&*,2*s&)))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))2R& CC& Case: 1:17-md-02804-DAP Doc #: 1225-2 Filed: 01/04/19 4 of 26. PageID #: 29649 €tft…jh‹j{h†hgfˆhj…•jg…†ljkljetthgi…vj‘…i…gf†p&& *,q&L)S)&-q-&r2V,4s&)))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))R& iot…ˆj€tft…jklj{nt†…gp& q+&M)_7&+*q&r*7&.C;)&2VVqs)))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))+& iot…ˆj€tft…jklj”hn“gotop& _,4&M)&SY\\)&*7&+V2&rQ)$)&#C[X)&*,,-s&)))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))2-& 90 476 M17)&J)&.C̀)&<)&_4ršsr*s))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))2q& M17)&J)&.C̀)&<)&_4ršsr*sr:srCCs&)))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))2q& M17)&J)&.C̀)&<)_4ršsr*sr.s&)))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))2R& %([/=&JY=1&_)4r7sr2s)))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))2+& %([/=&JY=1&+_)4&))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))4& %([/=&JY=1&+_)4ršs&)))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))2*& %([/=&JY=1&+_)4r7s&)))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))2R& KXC(&J)&<;(^)&.(97)&_)-&)))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))+& KXC(&J)&<;(^)&.(97)&_)R&)))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))2*p&2_p&2-p&24& KXC(&J)&<;(^)&.(97)&_)Rr/s&)))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))4& KXC(&J)&<;(^)&.(97)&-)2&)))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))+& KXC(&J)&<;(^)&.(97)&+)-&)))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))+p&24& 3 496803 9232476 $/9C1=&MC0X1;p&›K\C(C7&%/]a1;0&S/a&S1>>=1619>&#/a&8C9Z1&(9&M(;[C9Z&<=/C9>C^^0& H9>(&.=/00&:[>C(9pœ&hg“…&rS1\>)&*4p&*,2+sp& X>>\03]]])^(;š10)[(60C>10=1Z/=91]0=C91*,2+,V*4(\C(C75=/]a1;050/a5 01>>=1619>56/a5XC9Z15(95^(;[C9Z5\=/C9>C^^05C9>(5[=/005/[>C(9ž7-2,_7[272[^&)))))))))))))))))))))))))R& NC==&WXC>/Ÿ1;p&›K\C(C7&.;C0C03&IX1&%/]0YC>0&IX/>&.(Y=7&N/9Ÿ;Y\>&#/9Y^/[>Y;1;0& /97&$C0>;CšY>(;0pœ& ¡jxoint…jr$1[)&2Rp&*,2+sp& X>>\03]]])[š091]0)[(691]0(\C(C75[;C0C05/>>(;91a56CŸ156((;15>/Ÿ105(95 6/9Y^/[>Y;1;05/9757C0>;CšY>(;05/>5>X15[19>1;5(^5>X151\C716C[5R,56C9Y>10&)))))))))))))))))))))))))))))2& CCC& Case: 1:17-md-02804-DAP Doc #: 1225-2 Filed: 01/04/19 5 of 26. PageID #: 29650 K\C(C7&#/9Y^/[>Y;1;0&M;/Y7Y=19>&#/;Ÿ1>C9Z&%C>CZ/>C(9&MC;0>&J191]/=&(^& J1>19>C(9&:Z;11619>&rŽY=a&2p&*,24sp& X>>\03]]])(XC(/>>(;91aZ191;/=)Z(`MC=10%1Z/=KY>0C715 .(Y901=.(9>C9Z19[a5M115H9^(;6/>C(9K\C(C75#/9Y^/[>Y;1;05%C>CZ/>C(9)/0\¢&)))))))))))))))))))))))_& Ž1^&M11=1ap&›C9&I/;Z1>17&/>&ŽY7Z1T0&K\C(C7&SY66C>pœ&‚†hh}“…g‰ rM1š)&*p&*,2+sp&X>>\03]]])š=((6š1;Z)[(691]0/;>C[=10*,2+5,*5,*\Y;7Y15 05(¢a[(9>C950/C75>(5š15>/;Z1>175/>5£Y7Z1505(\C(C750Y66C>&)))))))))))))))))))))))))))))))))))))))))))))))))))))))q& Ž1^^&K`1;=1a&/97&Q6C=a&MC1=7p&›H90C71&>X1&K\C(C7&#$%T0&NCZ&.=(0175$((;& 81/;C9Zpœ&zfƒ¤ ¡&rM1š)&2p&*,2+sp& X>>\03]]])=/]_R,)[(6/;>C[=102,,+,2,C90C715>X15(\C(C7567=505šCZ5 [=(01757((;5X1/;C9Z&)))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))))q& C̀& Case: 1:17-md-02804-DAP Doc #: 1225-2 Filed: 01/04/19 6 of 26. PageID #: 29651 2139 50 32 16 %/]a1;0&;1\;1019>C9Z&\=/C9>C^^0&C9&>XC0&=C>CZ/>C(9&/;1&19Z/Z17&C9&/&[(9[1;>17&[/6\/CZ9&>(& >/C9>&\(>19>C/=&£Y;a&\((=0&C9&>XC0&7C0>;C[>¥/97&/[;(00&>X1&[(Y9>;a¥>X;(YZX&6C0=1/7C9Zp& C9^=/66/>(;ap&/97&C6\;(\1;&\Yš=C[&0>/>1619>0)&&IX1C;&š1X/`C(;p&]XC[X&;1/[X17&/&[;10[197(&(9& 9/>C(9/=&IU&7Y;C9Z&/&;1[19>&1\C0(71&(^& ¡jxoint…p&C0&/&^=/Z;/9>&`C(=/>C(9&(^&>X1C;&1>XC[/=& (š=CZ/>C(90&/0&/>>(;91a0&\;/[>C[C9Z&š1^(;1&>XC0&.(Y;>&/97&>X;1/>190&71^197/9>0T&;CZX>0&>(&/&^/C;& /7£Y7C[/>C(9&(^&>X1&[=/C60&/001;>17&/Z/C90>&>X16)&&.1;>/C9&0>/>1619>0&ša&\=/C9>C^^0T&[(Y901=&/=0(& X/`1&`C(=/>17&>XC0&.(Y;>T0&1¢\;100&(;71;0)&&IX101&=/]a1;0T&\;(^100C(9/=&6C0[(97Y[>&C0&0(&^/;& (Y>0C71&>X1&š(Y970&(^&/\\;(\;C/>1&š1X/`C(;&/0&>(&]/;;/9>&/&Z/Z&(;71;&/97&(>X1;&0/9[>C(90)&&SY[X& 0>1\0&/;1&91[100/;a&>(&X1=\&6C>CZ/>1&>X1&Y9^/C;&/97&\;1£Y7C[C/=&1^^1[>0&(^&>X1&6C0[(97Y[>&/97&>(& 71>1;&0C6C=/;&6C0[(97Y[>&C9&>X1&^Y>Y;1)&&IX1&10019>C/=&^/C;9100&(^&>XC0&\;([117C9Z&/97&>X1&;CZX>0&(^& >X1&\/;>C10&/;1&/>&0>/Ÿ1)& 8 308 6D8 ¦ 9 0156 K9&$1[16š1;&2Rp&*,2+p&.NS&/C;17&/9&1\C0(71&(^&C>0&9/>C(9/==a&š;(/7[/0>&>1=1`C0C(9&0X(]&  ¡jxoint…&>X/>&C9[=Y717&/&01Z619>&19>C>=17&›K\C(C7&.;C0C03&IX1&=/]0YC>0&>X/>&[(Y=7&š/9Ÿ;Y\>& 6/9Y^/[>Y;1;0&/97&7C0>;CšY>(;0)œ2&&$Y;C9Z&>X1&2_56C9Y>1&01Z619>p&>X;11&=/]a1;0&^(;&\=/C9>C^^0¥ #CŸ1&#((;1p&KXC(&:>>(;91a&P191;/=&r/97&P(`1;9(;51=1[>s&#CŸ1&$1WC91p&/97&NY;>(9&%1N=/9[¥ (^^1;17&>(&>X1&\Yš=C[&>X1&\=/C9>C^^0T&(9150C717&`C1]0&(^&>X1&[/01)&&WXC=1&#;)&#((;1p&#;)&$1WC91p& /97&#;)&%1N=/9[&]1;1&>X1&(9=a&=/]a1;0&]X(&]1;1&^1/>Y;17&(9&[/61;/p&>X1&`C71(&0X(]17&/>&=1/0>& >](&\=/C9>C^^0T&[(Y901=&0>;/>1Za&0100C(90&]C>X&01`1;/=&(>X1;&\=/C9>C^^0T&=/]a1;0&\;1019>p&/97&/=0(& 2&:&> ;/90[;C\>&/97&`C71(&;1[(;7C9Z&(^&>X1&01Z619>&C0&/`/C=/š=1&(9&.NST0&]1š0C>1&/>& X>>\03]]])[š091]0)[(691]0(\C(C75[;C0C05/>>(;91a56CŸ156((;15>/Ÿ105(956/9Y^/[>Y;1;05/975 7C0>;CšY>(;05/>5>X15[19>1;5(^5>X151\C716C[5R,56C9Y>10)&&M(;&[(9`19C19[1p&>X1&>;/90[;C\>&C0& />>/[X17&/>&Q¢XCšC>&2)&&NY>&>(&Y971;0>/97&>X1&^Y==&1¢>19>&(^&>X1&=/]a1;0T&6C0[(97Y[>p&71^197/9>0& 19[(Y;/Z1&>XC0&.(Y;>&>(&;1`C1]&>X1&`C71()& 2& Case: 1:17-md-02804-DAP Doc #: 1225-2 Filed: 01/04/19 7 of 26. PageID #: 29652 6/71&[=1/;&>X/>&9Y61;(Y0&(>X1;&=/]a1;0&^(;&>X1&\=/C9>C^^0&]1;1&/]/;1&(^&/97&C9`(=`17&C9&>X1& 1^^(;>)&&Q¢)&2&/>&_&r9(>C9Z&>X/>&]X19& ¡jxoint…&]/0&/>&#;)&#((;1T0&›[(66/97&[19>1;œ&›/š(Y>&/& 7(§19&=/]a1;0&^;(6&/==&/;(Y97&>X1&[(Y9>;aœ&]1;1&>X1;1&>((s)& IX1&=/]a1;0&]X(&/\\1/;17&C9&>X1& ¡jxoint…&01Z619>&[=/C617&>(&X/`1&;1`C1]17&7/>/& ^;(6&>X1&^171;/=&Z(`1;9619>T0&:J.KS&7/>/š/01&/97&/;;C̀17&/>&>X1&[(9[=Y0C(9&>X/>&>XC0& ›1`C719[1œ&10>/š=C0X10&>X1&71^197/9>0T&=C/šC=C>a)&&IX1a&^Y;>X1;&0YZZ10>17&>X/>&/9a&£Y;a&](Y=7& ;1/[X&>X1&0/61&[(9[=Y0C(9&/97&/]/;7&/0>;(9(6C[/=&7/6/Z10&/\\;(/[XC9Z&¨2,,&šC==C(9)&&:97&#;)& #((;1&]19>&(9&>(&[X/;/[>1;C§1&>X1&\=/C9>C^^0T&[/01&/Z/C90>&[1;>/C9&71^197/9>0&/0&\/;>C[Y=/;=a& ›1/0aœ&/97&›0C6\=1)œ&&Q¢)&2&/>&qp&R)&&IX1&=/]a1;0T&0>/>1619>0&C9[=Y717&>X1&^(==(]C9Z3& © ›H^&]1&>;a&>X1&KXC(&[/01p&C^&]1&]C9&/&`1;7C[>&/Z/C90>&>X101&6/9Y^/[>Y;1;0& /97&7C0>;CšY>(;0&>X1;1p&C>&[(Y=7&š/9Ÿ;Y\>&>X16)&&H>T7&\Y>&>X16&(Y>>/& šY0C9100)œ&&r#;)&#((;1s&rQ¢)&2&/>&*s& © ›ªW«X19&/&£Y;a&X1/;0&>X1&1`C719[1&C9&>XC0&[/01p&>X1aT;1&9(>&Z(99/&/]/;7& £Y0>&/&[(Y\=1&XY97;17&6C==C(9&7(==/;0)&&H>&6/a&š1&¨2,,&šC==C(9)œ&&r#;)& #((;1s&roˆls& © ›ªI«X1&0>(;C10&>X/>&a(YT`1&X1/;7&^;(6&0(61&(^&>X1&$Q:&ª$;YZ& Q9^(;[1619>&:76C9C0>;/>C(9«&C9`10>CZ/>C̀1&/Z19>0&[(9[1;9C9Z&>X1&=/;Z1& `(=Y610&(^&\C==0&Z(C9Z&C9>(&[1;>/C9&\/;>0&(^&(Y;&[(Y9>;a&/;1&/š0(=Y>1=a& >;Y1)œ&&r#;)&%1N=/9[p&C9&;10\(901&>(&/&¬Y10>C(9&/š(Y>&›>X1&6(0>&C6\(;>/9>& >XC9Zœ&X1&X/7&=1/;917&^;(6&>X1&:J.KS&7/>/s&roˆlj/>&4s& © ›HT6&9(>&/==(]17&>(&>/=Ÿ&/š(Y>&>X1&0\1[C^C[0)&&NY>&H&]C==&0C6\=a&>1==&a(Y&C>T0& 0X([ŸC9Z)&&:9a(91&]X(&]/0&=((ŸC9Z&/>&>X(01&9Y6š1;0p&/0&>X(01& 6C77=1619&]1;1p&/0&>X101&7C0>;CšY>(;0&]1;1p&[=1/;=ap&[=1/;=a&0X(Y=7T`1&0119& >X/>&0(61>XC9Z&]/0&7;/6/>C[/==a&];(9Z)œ&&r#;)&$1WC91s&roˆls& © ›H&7(9T>&>XC9Ÿ&>X1a&[/;17&19(YZX)&&:97&C^&>X1a&[/;17&19(YZXp&6/aš1&]1& ](Y=7&9(>&X/`1&=(0>&q,,p,,,&=C̀10&^;(6&>XC0&\;(š=16)&&H>T0¥C>&£Y0>¥C>& /\\/==0&61)œ&&r#;)&#((;1s&roˆls& © ›HT`1&0119&/==&>X1&6(71=0)&&I(&š1&1^^1[>C̀1p&]1&9117&/>&=1/0>&¨2,,&šC==C(9&>(& 0>/;>&(^^&]C>X)œ&&r#;)&#((;1p&C9&;10\(901&>(&/&¬Y10>C(9&/š(Y>&/6(Y9>0&>X1& \=/C9>C^^0&10>C6/>1&>X1a&](Y=7&9117&>(&^Y97&>;1/>619>p&\;1`19>C(9p&/97& 17Y[/>C(9&\;(Z;/60s&roˆls& *& Case: 1:17-md-02804-DAP Doc #: 1225-2 Filed: 01/04/19 8 of 26. PageID #: 29653 © ›'(š(7a&C9&>X1&](;=7T0&Z(99/&š1=C1`1&ª>X1&71^197/9>0T&/;ZY619>0&>X/>& >X1a&0X(Y=7&9(>&š1&š=/617&^(;&(\C(C7&/šY01«)&&:97¥/97&7(9T>&Z(&>;a&>(& >1==&>X/>&>(&2*&£Y;(;0&C9&#C00C00C\\C&(;&KXC(&]X(T`1&=(0>&\1(\=1&^;(6&>XC0)&& (Y&Ÿ9(]&]X/>¥r%:LP8s&a(Y&Ÿ9(]&]X/>&>X(01&£Y;(;0&/;1&Z(99/&7(­&& IX1aT;1&Z(99/&Z(&C9&>X1&š/[Ÿ&;((6p&>X1aT;1&Z(99/&0\197&/š(Y>&_,&6C9Y>10& >XC9ŸC9Z&/š(Y>&C>p&Z(99/&[(61&š/[Ÿ&(Y>&/97&š/6)œ&&r#;)&#((;1s&roˆl&/>&+s& #;)&#((;1&6C0=1/7C9Z=a&C6\=C17&X1&X/7&9(&\1;0(9/=&0>/Ÿ1&C9&>X1&=C>CZ/>C(9)&&€……&Q¢)&2&/>&4& r›H&7(9T>&[/;1&(91&]XC>&/š(Y>&/9a&6(91a&C9&>XC0&[/01)&&'(>&(91&]XC>&]X/>0(1`1;&/š(Y>&C>)œs)&&H9& ^/[>p&XC0&[(9>C9Z19[a&^11&/Z;11619>&]C>X&£Y0>&(91&(^&XC0&9Y61;(Y0&[=C19>0¥>X1&KXC(&:>>(;91a& P191;/=¥\;(`C710&^(;&XC6&>(&1/;9&6C==C(90&(^&7(==/;0&71\197C9Z&(9&>X1&(Y>[(61&(^&>X1&[/01)&j€…… X>>\03]]])(XC(/>>(;91aZ191;/=)Z(`MC=10%1Z/=KY>0C715.(Y901=.(9>C9Z19[a5M115H9^(;6/>C(9& K\C(C75#/9Y^/[>Y;1;05%C>CZ/>C(9)/0\¢)&&<;10Y6/š=a&X1&X/0&0C6C=/;&/;;/9Z1619>0&]C>X&XC0&(>X1;& [=C19>0)* #;)&%1N=/9[&6C0=1/7C9Z=a&0YZZ10>17&>X/>&>X1&71^197/9>0&X/7&/[[100&>(&>X1&:J.KS& 7/>/š/01&C9&>X1&(;7C9/;a&[(Y;01&/97&>X/>&>XC0&7/>/&0X(Y=7&X/`1&/=1;>17&>X16&>(&0Y0\C[C(Y0&\/>>1;90& (^&7C0>;CšY>C(9)&&€……joˆl&/>&4&rJ1\(;>1;3&&›$C7&>X1&[(6\/9C10&X/`1&/[[100&>(&>XC0&C9^(;6/>C(9&ª>X1& :J.KS&7/>/«­œ&&#;)&%1N=/9[3&&›H>&]/0&>X1C;&7/>/)œs®&……jf†hjoˆl&/>&*&r›H^&>X1a&7C79T>&Ÿ9(]&C>&>X1& ^C;0>&[(Y\=1&a1/;0p&>X1a&[=1/;=a&](Y=7T`1&0119&C>&/^>1;&>X/>)&&(Y&[/9T>&6C00&C>)&&WX19&(91&a1/;&]1& X/7&[=(01&>(&/&šC==C(9¥/&šC==C(9&\/C9&6170&\;10[;Cš17&C9&>X1&0>/>1&(^&KXC(p&a(Y&Ÿ9(]p&RV&\1;& 6/9p&](6/9p&/97&[XC=7&C9&>X1&0>/>1)&:97&>X/>&=C10&/>&>X1&^11>&(^&>X1&7;YZ&[(6\/9C10)&&IX1aT;1&>X1& (910&]X(&7C7&>X/>)œs&r#;)&$1WC91s)&&& NY>p&/0&\=/C9>C^^0T&[(Y901=&]1==&Ÿ9(]p&]XC=1&6/9Y^/[>Y;1;0&/97&7C0>;CšY>(;0&01\/;/>1=a& 0Yš6C>&C9^(;6/>C(9&>(&>X1&$Q:&^(;&C9[=Y0C(9&C9&>X1&:J.KS&7/>/š/01p&>X1a&7(&9(>&X/`1&/[[100&>(& >X1&7/>/š/01&C>01=^&(;&>(&>X1&C9^(;6/>C(9&0Yš6C>>17&ša&(>X1;&6/9Y^/[>Y;1;0&/97&7C0>;CšY>(;0)&&H9& *&#;) &#((;1&C0&[(Y901=&(^&;1[(;7&^(;&/>&=1/0>&>X;11&\=/C9>C^^0&C9&>XC0&#$%&r8/6C=>(9&.(Y9>ap& I19910011®&8C==0š(;(YZX&.(Y9>ap&M=(;C7/®&/97&>X1&.C>a&(^&I/6\/p&M=(;C7/sp&/0&]1==&/0&>X1&S>/>1&(^& KXC(p&>X1&S>/>1&(^&:;Ÿ/90/0p&/97&S/=>&%/Ÿ1&.(Y9>ap&L>/X)&&& _& Case: 1:17-md-02804-DAP Doc #: 1225-2 Filed: 01/04/19 9 of 26. PageID #: 29654 >XC0&`1;a&\;([117C9Zp&>X1&L9C>17&S>/>10&X/0&16\X/0C§17&>X/>&›>X1&7/>/&[(9>/C90&=/]&19^(;[1619>& 0190C>C̀1&/97&<;C̀/[a&:[>&\;(>1[>17&C9^(;6/>C(9pœ&C9[=Y7C9Z&›[(9^C719>C/=&šY0C9100&;1[(;70&/97& >;/71&01[;1>0&ša&>X1&;1\(;>C9Z&[(6\/9C10pœ&/97&>XY0&›$Q:&7(10&9(>&;1=1/01&:J.KS&7/>/&\Yš=C[=a& /97&(9=a&\;(7Y[17&C>&ªC9&>XC0&/[>C(9«&Y971;&>X1&0/^1ZY/;70&(^&>X1&<;(>1[>C̀1&K;71;)œ&&iot…ˆj€tft…j h‹je}…gof–j‚go…‹joij€n~~hgtjh‹j™“¯…tohijthjmo†hng…jh‹jeŠ{™€jmftfp&Q.M&424&/>&*)&&& :97&/0&>XC0&.(Y;>&\;1`C(Y0=a&;1[(Z9C§17p&›ª1«¢>190C̀1&^171;/=&=/]0&/97&;1ZY=/>C(90&=C6C>& >X1&[C;[Y60>/9[10&C9&]XC[X&>X1&$Q:&6/a&7C0[=(01&:J.KS&7/>/pœ&C9[=Y7C9Z&7/>/&0Yš6C>>17&ša& ;1\(;>C9Z&[(6\/9C10)&&K\)&°&K;71;p&Q.M&+,,&/>&2,)&&IX1&:J.KS&7/>/š/01&C0&Y017&ša&>X1&^171;/=& Z(`1;9619>&^(;&=/]&19^(;[1619>&\Y;\(010&/97&>X1&^Y==&[(6\C=/>C(9&(^&7/>/&\;(`C710&/&^/;&6(;1& [(6\;1X190C̀1&`C1]&(^&\;10[;C\>C(9&(\C(C7&7C0>;CšY>C(9&>X/9&/9a&C97C̀C7Y/=&6/9Y^/[>Y;1;&(;& 7C0>;CšY>(;&](Y=7&1`1;&X/`1)&&M(;&>XC0&;1/0(9p&>X1&7/>/š/01&[(Y=7&91`1;&š1&/76C00Cš=1&>(&10>/š=C0X& /9a&71^197/9>T0&Ÿ9(]=17Z1&(^&/==&(^&>X1&C9^(;6/>C(9&[(9>/C917&]C>XC9&C>)&&#;)&%1N=/9[T0& 0YZZ10>C(9&>(&>X1&[(9>;/;a&]/0&^/=01p&/97&X1&Ÿ91]&C>&/>&>X1&>C61)& IX1;1&[/9&š1&9(&7(Yš>&>X/>&>X101&=/]a1;0T&\Y;\(01&C9&0\1/ŸC9Z&>(&>X1&\;100&]/0&>(&C9^=/61& \Yš=C[&019>C619>&/Z/C90>&>X1&71^197/9>0&/97&C6\/C;&>X1C;&/šC=C>a&>(&;1[1C̀1&/&^/C;&X1/;C9Z)&&#;)& #((;1&/76C>>17&/0&6Y[X3&&›:&[/01&C9&[(Y;>&C0&/&[/01&C9&[(Y;>p&/97&>X/>T0&^C91)&&NY>&>X1;1T0&/=0(&>X1& [(Y;>&(^&\Yš=C[&(\C9C(9)&&:97&>X1&[(Y;>&(^&\Yš=C[&(\C9C(9&C0&0(61>C61&ª0C[«&>X1&6(0>&\(]1;^Y=& [(Y;>)œ&&Q¢)&2&/>&_)&&:[[(;7C9Z&>(&>X1&;1\(;>1;p&#;)&#((;1&/>>;CšY>17&XC0&0Y[[100&C9&\;C(;&=C>CZ/>C(9& /Z/C90>&>(š/[[(&[(6\/9C10&›6(0>=aœ&>(&›Z(C9Z&\Yš=C[pœ&/97&0YZZ10>17&>X/>&X1&]/0&Y0C9Z&>X1&0/61& ›\=/aš((Ÿœ&X1;1&>(&›šYC=7&=1Z/=&/97&\Yš=C[&\;100Y;1&Y9>C=&>X1&[(6\/9C10&011&9(&[X(C[1&šY>&>(& 01>>=1p&/97&^(;Ÿ&(`1;&šC==C(90)œ&& ˆl&/>&q)_ _&K^ &[(Y;01p&>X1;1&/;1&9Y61;(Y0&7C^^1;19[10&š1>]119&#;)&#((;1T0&\;1`C(Y0&=C>CZ/>C(9&/Z/C90>& >(š/[[(&[(6\/9C10&/97&>X1&[Y;;19>&=C>CZ/>C(9&/Z/C90>&(\C(C7&6/9Y^/[>Y;1;0&/97&7C0>;CšY>(;0)&&M(;& 0>/;>1;0p&(\C(C7&617C[/>C(90&/;1&M$:&/\\;(`17p&/`/C=/š=1&(9=a&>X;(YZX&/&\;10[;C\>C(9p&/97& -& Case: 1:17-md-02804-DAP Doc #: 1225-2 Filed: 01/04/19 10 of 26. PageID #: 29655 WX19&71^197/9>0&^C;0>&=1/;917&/š(Y>&.NST0&\=/9917&š;(/7[/0>¥^;(6&/&>1/01;&.NS&/C;17& ^1/>Y;C9Z&0(61&(^&>X1&0>/>1619>0&C719>C^C17&/š(`1¥>X1a&\;(6\>=a&;1/[X17&(Y>&>(&\=/C9>C^^0T& [(Y901=&>(&`(C[1&>X1C;&[(9[1;90&/97&;1¬Y10>&/\\;(\;C/>1&\;1`19>C̀1&(;&;1617C/=&/[>C(90&›š1^(;1& >X1&01Z619>&/C;0&/97&\(>19>C/==a&[/Y010&0CZ9C^C[/9>&/97&C;;1\/;/š=1&X/;6&>(&(91&(;&6(;1& 71^197/9>0)œ&&Q¢)&*&r%>;)&^;(6&#)&.X1^^(&>(&:>>(;91a&P191;/=&#)&$1WC91p&$1[)&2Rp&*,2+s)&& <=/C9>C^^0T&[(Y901=&91`1;&1`19&;10\(9717)&& <=/C9>C^^0T&[(Y901=T0&\/;>C[C\/>C(9&C9&>X1& ¡jxoint…&01Z619>&]/0&9(>&/9&C0(=/>17&C9[C719>)&& IX1a&X/`1&6/71&(>X1;&C6\;(\1;&/97&C9^=/66/>(;a&1¢>;/£Y7C[C/=&0>/>1619>0&/š(Y>&>X1&71^197/9>0)&& M(;&1¢/6\=1p&C9&M1š;Y/;a&*,2+p&>X1&71^197/9>0&\;(`C717&>XC0&.(Y;>&]C>X&9Y61;(Y0&\;100&;1\(;>0& ¬Y(>C9Z&6C0=1/7C9Z&0>/>1619>0&6/71&ša&\=/C9>C^^0T&[(Y901=&7Y;C9Z&/&01>>=1619>&[(9^1;19[1p&/0& ]1==&/0&>XC0&.(Y;>T0&`C1]&(^&>X1&C9^(;6/>C(9&>X/>&]/0&\;1019>17&7Y;C9Z&>X1&[(9^1;19[1)&&€……jŽ1^^& K`1;=1a&/97&Q6C=a&MC1=7p&›H90C71&>X1&K\C(C7&#$%T0&NCZ&.=(0175$((;&81/;C9Zpœ&zfƒ¤ ¡&rM1š)& 2p&*,2+sp&X>>\03]]])=/]_R,)[(6/;>C[=102,,+,2,C90C715>X15(\C(C7567=505šCZ5[=(01757((;5 X1/;C9Z®&Ž1^&M11=1ap&›C9&I/;Z1>17&/>&ŽY7Z1T0&K\C(C7&SY66C>pœ&‚†hh}“…g‰&rM1š)& *p&*,2+sp&X>>\03]]])š=((6š1;Z)[(691]0/;>C[=10*,2+5,*5,*\Y;7Y1505(¢a[(9>C950/C75>(5š15 >/;Z1>175/>5£Y7Z1505(\C(C750Y66C>)&&IX1&`1;a&91¢>&7/ap&>XC0&.(Y;>&C00Y17&/9&(;71;&\;1[=Y7C9Z& [(Y901=&^;(6&7C0[=(0C9Z&>X1&[(9>19>&(^&>X1&01>>=1619>&7C0[Y00C(90&(;&\;(`C7C9Z&/9a&[(6619>/;a& (9&>X16)&&Q.M&22R)&&'(>]C>X0>/97C9Z&>X1&.(Y;>T0&(;71;p&\=/C9>C^^0T&[(Y901=&X/`1&[(9>C9Y17&>(& C9>19717&>(&š1&Y017&Y971;&>X1&[/;1^Y=&0Y\1;`C0C(9&(^&/&\Xa0C[C/9&/97&(9=a&/0&\;10[;Cš17)&& #(;1(`1;p&6/9Y^/[>Y;1;0&/97&7C0>;CšY>(;0&\=/a&7C0>C9[>&;(=10&C9&>X1&\X/;6/[1Y>C[/=&0Y\\=a&[X/C9)&& IX1&\=/C9>C^^0T&1^^(;>0&>(&X(=7&6/9Y^/[>Y;1;0&/97&7C0>;CšY>(;0&(^&>X101&C6\(;>/9>p&M$:5/\\;(`17& 617C[/>C(90&=C/š=1&^(;&>X1&[(901¬Y19[10&(^&(>X1;0T&6C0Y01&/97&/šY01¥/0&]1==&/0&>X1&/[>C̀C>C10&(^& C==1Z/=&7;YZ&[/;>1=0&^=((7C9Z&>X1&0>;11>0&]C>X&X1;(C9&/97&^19>/9a=¥š1/;&9(&;1016š=/9[1&>(&>X1& >(š/[[(&=C>CZ/>C(9p&/97&\=/C9>C^^0T&=1Z/=&>X1(;C10&X/`1&91`1;&š119&/\\=C17&C9&>XC0&[(9>1¢>)&& #(;1(`1;p&>X1&;C0Ÿ&(^&/77C[>C(9&>(&(\C(C70&X/0&š119&[(66(9&Ÿ9(]=17Z1&^(;&[19>Y;C10p&/97&>XC0& ;C0Ÿ&]/0&/>&/==&;1=1`/9>&>C610&\;(6C919>=a&7C0[=(017&C9&>X1&M$:5/\\;(`17&=/š1=C9Z&^(;&>X1&(\C(C7& 617C[/>C(90&6/9Y^/[>Y;17&(;&7C0>;CšY>17&ša&>X1&`/;C(Y0&71^197/9>0)& q& Case: 1:17-md-02804-DAP Doc #: 1225-2 Filed: 01/04/19 11 of 26. PageID #: 29656 6/Ÿ1&C6\;(\1;&1¢>;/£Y7C[C/=&0>/>1619>0&/š(Y>&>X1&[(9^C719>C/=&01>>=1619>&7C0[Y00C(90p&7C̀Y=Z1& /97&6C0[X/;/[>1;C§1&C9^(;6/>C(9&\;1019>17&7Y;C9Z&>X(01&7C0[Y00C(90p&/97&=(7Z1&C9^=/66/>(;a& ;16/;Ÿ0&/97&/7&X(6C916&/>>/[Ÿ0&/Z/C90>&>X1&71^197/9>0)&&€……yj…l‰lp&$/9C1=&MC0X1;p&›K\C(C7& %/]a1;0&S/a&S1>>=1619>&#/a&8C9Z1&(9&M(;[C9Z&<=/C9>C^^0&H9>(&.=/00&:[>C(9pœ&hg“…&rS1\>)&*4p& *,2+sp&X>>\03]]])^(;š10)[(60C>10=1Z/=91]0=C91*,27+,V*4(\C(C75=/]a1;050/a501>>=1619>5 6/a5XC9Z15(95^(;[C9Z5\=/C9>C^^05C9>(5[=/005/[>C(9ž7-2,_7[272[^)&&& :0&C0&[=1/;&^;(6&>X1C;&;1\1/>17&6C0[(97Y[>¥/97&#;)&#((;1T0&(]9&/76C00C(9¥C>&C0& \=/C9>C^^0T&[(Y901=T0&C9>19>&>(&;C=1&Y\&>X1&\Yš=C[p&>/C9>&>X1&`C1]0&(^&\;(0\1[>C̀1&£Y;(;0&]C>X& 6C0[X/;/[>1;C§/>C(90&(^&›1`C719[1œ&]XC[X&rC^&/76C00Cš=1&/>&/==s&[(Y=7&91`1;&š1&Y017&C9&/&[(Y;>&(^& =/]&C9&>X1&]/a&\=/C9>C^^0T&[(Y901=&0YZZ10>17p&/97&;1971;&C>&C6\(00Cš=1&^(;&71^197/9>0&>(&;1[1C̀1&/& ^/C;&/7£Y7C[/>C(9&(^&>X1&[=/C60&/001;>17&/Z/C90>&>X16)&&IXC0&C0&]X(==a&C9/\\;(\;C/>1p&Y91>XC[/=& š1X/`C(;p&/97&Y9^(;>Y9/>1=a&>XC0&.(Y;>T0&\;C(;&1^^(;>0&>(&0>(\&C>&X/`1&š119&C91^^1[>C̀1)&&H>&C0&9(]& >C61&^(;&0>;(9Z1;&0/9[>C(90)& 89 0@4136 2± 82132 7?6 0174 6 2 834563 46 2 690 476 6 9 4772 18 6 150 3±6 H>&C0&/&š17;([Ÿ&\;C9[C\=1&(^&(Y;&£Y7C[C/=&0a0>16&>X/>&>X1&=/]&C0&>(&š1&71[C717&ša&[(Y;>0p&/97& 7C0\Y>17&^/[>0&/;1&(;7C9/;C=a&>(&š1&71[C717&ša&/&£Y;ap&š/017&(9&/76C00Cš=1&1`C719[1&\;1019>17&C9&/& [(Y;>;((6&7Y;C9Z&>;C/=)&&€……j€tft…jh‹j{h†hgfˆhj…•jg…†ljkljetthgi…vj‘…i…gf†p&*,q&L)S)&-q-p&-R*& r2V,4s&r8(=610p&Ž)s&r›IX1&>X1(;a&(^&(Y;&0a0>16&C0&>X/>&>X1&[(9[=Y0C(90&>(&š1&;1/[X17&C9&/&[/01& ]C==&š1&C97Y[17&(9=a&ša&1`C719[1&/97&/;ZY619>&C9&(\19&[(Y;>p&/97&9(>&ša&(Y>0C71&C9^=Y19[1p& ]X1>X1;&(^&\;C̀/>1&>/=Ÿ&(;&\Yš=C[&\;C9>)œs)&&IX101&^Y97/619>/=&/0\1[>0&(^&7Y1&\;([100&/;1&;1¬YC;17& >(&ZY/;/9>11&/&^/C;&/7£Y7C[/>C(9&(^&[=/C60)&& R& Case: 1:17-md-02804-DAP Doc #: 1225-2 Filed: 01/04/19 12 of 26. PageID #: 29657 Q¢>;/£Y7C[C/=&0>/>1619>0&ša&=/]a1;0&\(01&/&\/;>C[Y=/;&›>X;1/>&>(&>X1&^/C;9100&(^&/&\197C9Z& \;([117C9Z)œ&&‘…ito†…jklj€tft…j‚fgjh‹jŒ…kfˆfp&q,2&L)S)&2,_,p&2,4-&r2VV2s)&&N1[/Y01&(^&>X1C;& \;(^100C(9/=&0>/97C9Zp&/97&š1[/Y01&›=/]a1;0&X/`1&0\1[C/=&/[[100&>(&C9^(;6/>C(9&>X;(YZX& 7C0[(`1;a&/97&[=C19>&[(66Y9C[/>C(90pœ&=/]a1;0T&\Yš=C[&[(6619>0&/š(Y>&/&[/01&›/;1&=CŸ1=a&>(&š1& ;1[1C̀17&/0&10\1[C/==a&/Y>X(;C>/>C̀1)œ&& ˆ)&&I(&ZY/;7&/Z/C90>&>XC0&;C0Ÿp&>X1&;Y=10&(^&\;(^100C(9/=& ;10\(90CšC=C>a&1¢\;100=a&\;(XCšC>&>X1&=/]a1;0&C9`(=`17&C9&/&6/>>1;&^;(6&6/ŸC9Z&1¢>;/£Y7C[C/=& 0>/>1619>0&=CŸ1=a&>(&\;1£Y7C[1&/&\/;>aT0&/šC=C>a&>(&;1[1C̀1&/&^/C;&/7£Y7C[/>C(9)&&M(;&1¢/6\=1p&JY=1& _)Rr/s&(^&>X1&KXC(&JY=10&(^&<;(^100C(9/=&.(97Y[>&\;(`C7103& :&=/]a1;&]X(&C0&\/;>C[C\/>C9Z&(;&X/0&\/;>C[C\/>17&C9&>X1&C9`10>CZ/>C(9&(;&=C>CZ/>C(9& (^&/&6/>>1;&0X/==&9(>&6/Ÿ1&/9&1¢>;/£Y7C[C/=&0>/>1619>&>X/>&>X1&=/]a1;&Ÿ9(]0&(;& ;1/0(9/š=a&0X(Y=7&Ÿ9(]&]C==&š1&7C0016C9/>17&ša&61/90&(^&\Yš=C[&[(66Y9C[/>C(9& /97&]C==&X/`1&/&0Yš0>/9>-C/=&=CŸ1=CX((7&(^&6/>1;C/==a&\;1£Y7C[C9Z&/9&/7£Y7C[/>C̀1& \;([117C9Z&C9&>X1&6/>>1;) #;)&#((;1p&#;)&$1WC91p&/97&#;)&%1N=/9[&X/`1&š=/>/9>=a&`C(=/>17&>XC0&;Y=1)&&Q/[X&(^& >X16&6/71&1¢>;/£Y7C[C/=&0>/>1619>0p&Ÿ9(]C9Z&>X/>&>X1a&](Y=7&š1&9/>C(9/==a&>1=1`C017&(9&  ¡jxoint…p&^(;&>X1&1¢\;100&\Y;\(01&(^&[;1/>C9Z&(`1;]X1=6C9Z&\Yš=C[&\;100Y;1&(9&>X1&71^197/9>0& >(&01>>=1)&&IX1a&1¢\;10017&(\C9C(90&/š(Y>&>X1&61;C>0&(^&>X1&=C>CZ/>C(9p&C90C9Y/>C9Z&>X/>&>X1a&X/7& ;1`C1]17&›1`C719[1œ&10>/š=C0XC9Z&>X1&71^197/9>0T&=C/šC=C>a)&&€……jmh…jkljŠh…p&'()&.U52q5,4q,_p& *,2R&W%&V2,42_4p&/>&²q&r.)$)&./=)&S1\>)&_,p&*,2Rs&rC>&C0&C6\;(\1;&>(&[(6619>&(9&›>X1&0>;19Z>X0& (;&]1/Ÿ910010&(^&/9a&\/;>aT0&[/01œs)&&IX1a&6C0[X/;/[>1;C§17&>XC0&0Y\\(017&›1`C719[1œ¥>X1& :J.KS&7/>/¥C6\=aC9Zp&^(;&C90>/9[1p&>X/>&C>&]/0&]C>XC9&1/[X&71^197/9>T0&\(00100C(9&]X19&>X1a& Ÿ91]&C>&]/0&9(>)&&Q¢&2)&/>&R)IX1a&0YZZ10>17&>X/>&/&£Y;a&0X(Y=7&/]/;7&0Y60&710CZ917&>(&š/9Ÿ;Y\>& 71^197/9>0p&1`19&Z(C9Z&0(&^/;&/0&>(&C719>C^a&\/;>C[Y=/;&/6(Y9>0)&& ˆl&/>&2)&:97&>X1a&[(6619>17& -& :>>(;91a0&\;/[>C[C9Z&š1^(;1&>XC0&.(Y;>¥]X1>X1;&>X1a&/;1&616š1;0&(^&>X1&š/;&(^&>XC0&.(Y;>&(;& /76C>>17&^(;&\Y;\(010&(^&/&\/;>C[Y=/;&\;([117C9Z¥/;1&š(Y97&ša&>X1&KXC(&JY=10&(^&<;(^100C(9/=& .(97Y[>)&&€……yj…l‰lp%([/=&JY=1&+_)4®j……jf†hjeituhivjwljxfitofyjzz{jklj }~ftj€~hgtyj ilp& '()&_3,V5[`5_R*p&*,22&W%&2_*_*-++p&/>&²2&rS)$)&KXC(&'(`)&+p&*,22s)& 4& Case: 1:17-md-02804-DAP Doc #: 1225-2 Filed: 01/04/19 13 of 26. PageID #: 29658 (9&›>X1&[X/;/[>1;&(;&;1\Y>/>C(9œ&(^&>X1&71^197/9>0p&/[[Y0C9Z&(91&(^&>X16&(^&=aC9Z&/97&(>X1;0&(^& =/[ŸC9Z&›]/=ŸC9Z&/;(Y97&01901œ&/97&›9(>&[/;ªC9Z«&19(YZX)œ&&€……jefghijkljmnggfiop&'()&232_5[`5 *,*p&*,2_&W%&2*2*2q2Rp&/>&²2&rS)$)&KXC(&K[>)&2p&*,2_s&r^C97C9Z&[(Y901=T0&›71;(Z/>(;a& [(6619>0œ&/š(Y>&71^197/9>0&>(&š1C6\;(\1;&1¢>;/£Y7C[C/=&0>/>1619>0s®&mh…p&*,2R&W%&V2,42_4p& />&²q&rC>&C0&C6\;(\1;&>(&7C0[Y00&›>X1&[X/;/[>1;&(;&;1\Y>/>C(9&(^&>X1&\/;>C10œs)&&& IX101&0(;>0&(^&0>/>1619>0&](Y=7&9(>&š1&\1;6C00Cš=1&C9&/&[(Y;>;((6&7Y;C9Z&/&>;C/=)&&€……j KXC(&J)&<;(^)&.(97)&_)-&r/>&>;C/=p&/&=/]a1;&6/a&9(>&›/001;>&\1;0(9/=&Ÿ9(]=17Z1&(^&^/[>0&C9&C00Y1& )&)&)&(;&0>/>1&/&\1;0(9/=&(\C9C(9&/0&>(&>X1&£Y0>9100&(^&/&[/Y01p&>X1&[;17CšC=C>a&(^&/&]C>9100p&>X1& [Y=\/šC=C>a&(^&/&[C̀C=&=C>CZ/9>p&(;&>X1&ZYC=>&(;&C99([19[1&(^&/9&/[[Y017œs®&KXC(&J)&<;(^)&.(97)&-)2& r/&=/]a1;&6/a&9(>&Ÿ9(]C9Z=a&›6/Ÿ1&/&^/=01&0>/>1619>&(^&6/>1;C/=&^/[>&(;&=/]&>(&/&>XC;7&\1;0(9œs)&& :97&>X1;1&C0&9(&=1ZC>C6/>1&1¢[Y01&^(;&/9a&(^&>X101&=/]a1;0&>(&X/`1&6/71&>X16&(Y>0C71&>X1& [(Y;>;((6&^(;&/9a&;1/0(9p&6Y[X&=100&]C>X&>X1&0>/>17&C9>19>&>(&Z191;/>1&\;1>;C/=&\Yš=C[C>a& 71>;C619>/=&>(&>X1&71^197/9>0)&&<=/C9>C^^0T&[(Y901=T0&0>/>1619>0&›]1;1&7C\\17&C9&`19(6&/97&]1;1& 71=Cš1;/>1=a&[(Y[X17&>(&\(C0(9&>X1&]1==&^;(6&]XC[X&>X1&£Y;a&](Y=7&š1&01=1[>17)&&SY[X&[(97Y[>& Z(10&š1a(97&>X1&\/=1p&ša&/9a&;1/0(9/š=1&0>/97/;7p&/97&[/99(>&š1&[(97(917&Y971;&>X1&;Yš;C[&(^& ³1^^1[>C̀1&/7`([/[a)Tœjjiot…ˆj€tft…jklj{nt†…gp&q+&M)_7&+*qp&+-,&r*7&.C;)&2VVqs)&& K>X1;&=/]a1;0&]X(&\/;>C[C\/>17&C9&>X1&\=/99C9Z&(;&1¢1[Y>C(9&(^&>XC0&0[X161&X/`1&=CŸ1]C01& `C(=/>17&>X1C;&1>XC[/=&(š=CZ/>C(90)&&JY=1&+)-&(^&>X1&KXC(&JY=10&(^&<;(^100C(9/=&.(97Y[>&6/Ÿ10&/& =/]a1;&]X(&›Ÿ9(]C9Z=a&/00C0>ª0«&(;&C97Y[1ª0«&/9(>X1;&>(&ª`C(=/>1&>X1&KXC(&JY=10&(^&<;(^100C(9/=& .(97Y[>«p&(;&7(ª10«&0(&>X;(YZX&>X1&/[>0&(^&/9(>X1;pœ&£Y0>&/0&;10\(90Cš=1&/0&>X1&=/]a1;&]X(& [(66C>0&>X1&Y971;=aC9Z&`C(=/>C(9)& MC9/==ap&#;)&#((;1T0&0YZZ10>C(9&>X/>&X1&](Y=7&9(>&;1[1C̀1&›(91&]XC>œ&(^&6(91a&^;(6&>XC0& =C>CZ/>C(9&]/0&^/=01)&&#;)&#((;1&C0&/&\;C̀/>1&/>>(;91a&](;ŸC9Z&^(;&01`1;/=&\=/C9>C^^0&C9&/97&(Y>0C71& +& Case: 1:17-md-02804-DAP Doc #: 1225-2 Filed: 01/04/19 14 of 26. PageID #: 29659 (^&>XC0&#$%)&&8C0&[(9>C9Z19[a&^11&/Z;11619>&]C>X&>X1&S>/>1&(^&KXC(&/=(91&\;(`C710&^(;&XC6&/97& XC0&[(5[(Y901=&>(&;1[1C̀1&Y\&>(&¨q,&6C==C(9&71\197C9Z&(9&>X1&(Y>[(61&(^&>X1&[/01)&&81& \;10Y6/š=a&X/0&0C6C=/;&/Z;11619>0&]C>X&XC0&(>X1;&[=C19>0)&&& 8C0&0>/>1619>0&/0&>(&>X1&\(>19>C/=&`/=Y1&(^&/&£Y;a&/]/;7&]1;1&0C6C=/;=a&C;;10\(90Cš=1)&&H9& (\C9C9Z&>X/>&>X1&`/=Y1&(^&/9&/]/;7&›6/a&š1&¨2,,&šC==C(9pœ&Q¢)&2&/>&*p&4p&#;)&#((;1&Ÿ91]&>X/>&XC0& /Y7C19[1&](Y=7&C9[=Y71&\(>19>C/=&£Y;(;0&/97&a1>p&C9&>;/90\/;19>&01=^5C9>1;10>p&X1&9(91>X1=100& />>16\>17&>(&/9[X(;&C9&>X1&6C970&(^&>X1&\Yš=C[&/97&^Y>Y;1&£Y;a&\((=0&/&7(==/;&`/=Y1&š/017&(9&XC0& (]9&;1\;1019>/>C(90&/š(Y>&Y90\1[C^C17&›6(71=0)œ&&8C0&/>>16\>&>(&šC/0&\Yš=C[&(\C9C(9&/97&>X1&£Y;a& >(]/;7&/&`C1]&/š(Y>&>X1&`/=Y1&(^&>X1&[/01&C0&/&0>Y99C9Z&/97&C9/\\;(\;C/>1&/[>&;((>17&C9&01=^5 C9>1;10>)&&& 22± 82132 7?6 0174 6 2 83456 0936 95497±66 WX19&>XC0&.(Y;>&\1;6C>>17&\=/C9>C^^0T&[(Y901=&/97&0>/>1&/>>(;91a0&Z191;/=&0Y[X&/0&#;)& $1WC91&/[[100&>(&:J.KS&7/>/p&C>&0>;10017&>X1&1¢>;161=a&=C6C>17&\Y;\(010&^(;&]XC[X&>X1&7/>/& [(Y=7&š1&Y017)&&IX1&.(Y;>&;1\1/>17=a&0>/>17&>X/>&>X1&:J.KS&7/>/&[(Y=7&š1&Y017&^(;&(9=a&>](& \Y;\(010¥›>XC0&=C>CZ/>C(9œ&(;&›=/]&19^(;[1619>œ¥/97&](Y=7&9(>&š1&6/71&\Yš=C[)&&Q.M&2qR&/>& 2_3R5Vp&2_52-®&oˆl&/>&-*3R524p&-R3**5*qp&-4325qp&4,3*,5*_®&……jf†hjQ.M&2R4&/>&_&r[(9^C719>C/=& :J.KS&7/>/&›0X/==&9(>&š1&Y017&ša&>X1&\/;>C10p&[(Y901=&^(;&>X1&\/;>C10p&(;&/9a&(>X1;&/Y>X(;C§17& \1;0(90&C719>C^C17&C9&´&R&^(;&/9a&\Y;\(01&]X/>0(1`1;&(>X1;&>X/9&r2s&>(&617C/>1p&01>>=1p&\;(01[Y>1p& (;&71^197&>X1&/š(`15[/\>C(917&=C>CZ/>C(9p&(;&r*s&^(;&=/]&19^(;[1619>&\Y;\(010œs®&Q.M&*__&/>&**& r›L01&(^&:J.KS&7/>/š/01&0X/==&š1&=C6C>17&>(&>XC0&=C>CZ/>C(9&/97&^(;&S>/>1&/97&=([/=&=/]& 19^(;[1619>&\Y;\(010&(9=a)&&'(&\1;0(9&0X/==&7C0[=(01&>X1&7/>/&(;&/==(]&Y01&(^&>X1&7/>/&1¢[1\>&/0& 91[100/;a&^(;&/&0Yš6C00C(9&>(&>X1&[(Y;>&(;&/>&>;C/=)œs®&Q.M&_V4&/>&_&r0/61s)&&& :0&^(;&\(>19>C/=&7C0[=(0Y;1&>(&>X1&\;100p&>XC0&.(Y;>&]/0&Y91¬YC̀([/=3&&C>&(;71;17&>X/>& [(9^C719>C/=&:J.KS&7/>/&›0X/==&9(>&š1&[(66Y9C[/>17&>(&>X1&\Yš=C[&(;&617C/&µ¶ ·¶¸ ¹·¸ º» ¼º»½ V& Case: 1:17-md-02804-DAP Doc #: 1225-2 Filed: 01/04/19 15 of 26. PageID #: 29660 ]C>X(Y>&\;C(;&/\\;(`/=&(^&>X1&.(Y;>)œ&&Q.M&2R4&/>&-&r16\X/0C0&/7717s®&……jf†hjQ.M&+,,&/>&22& r›:==(]C9Z&>X1&:J.KS&7/>/&>(&š1&7C0[=(017&>(&>X1C/&)&)&)&](Y=7&1`C0[1;/>1&>X1&.(Y;>T0& <;(>1[>C̀1&K;71;)œs)&&IX1&\/;>C10p&>X1C;&=/]a1;0p&/97&0>/>1&/>>(;91a0&Z191;/=&0Y[X&/0&#;)&$1WC91& /;1&/==&š(Y97&ša&>XC0&(;71;)&&Q.M&2R4&/>&-®&Q.M&R-,&/>&2®&……jf†h&2**,2+&#C9Y>10&/97&K;71;p& Q.M&2*,R) $Y;C9Z&>X1C;&/\\1/;/9[10&(9& ¡jxoint…p&#;)&#((;1p&#;)&$1WC91p&/97&#;)&%1N=/9[& ^=/Z;/9>=a&`C(=/>17&>X101&[(Y;>5(;71;17&;10>;C[>C(90&ša&;1\1/>17=a&7C0[Y00C9Z&/97&[X/;/[>1;C§C9Z& >X1&[(9^C719>C/=&:J.KS&7/>/&>X/>&X/7&š119&\;(7Y[17&>(&>X16)&&H9&^/[>p&/&0CZ9C^C[/9>&\(;>C(9&(^& >X1& ¡jxoint…j01Z619>&^([Y017&(9&>X1&›XYZ1&[(9^C719>C/=&$Q:&7/>/š/01&[/==17&:J.KSpœ&]XC[X& #;)&#((;1&/97&›XC0&/==C10œ&[X/;/[>1;C§17&/0&›\(]1;^Y=œ&/97&›71`/0>/>C9Zœ&1`C719[1)&&Q¢)&2&/>&2p& R)&&H9&Y0C9Z&>X1&:J.KS&7/>/&>(&6/Ÿ1&>X1C;&[/01&>(&>X1&›[(Y;>&(^&\Yš=C[&(\C9C(9pœ&/==&>X;11& />>(;91a0&`C(=/>17&>X1&\;(>1[>C̀1&(;71;&01`1;/=&>C610&(`1;)&&& #;)&%1N=/9[&1`C719>=a&>(=7&>X1&;1\(;>1;&>X/>&›XC0&>1/6œ&X/7&>/Ÿ19&›>X1&=1/7&C9&/9/=a§C9Z& >X1&:J.KS&7/>/)œ&&Q¢)&2&/>&R)&&81&š(/0>17&>(&>X1&/Y7C19[1&>X/>&X1&[(Y=7&›/[>Y/==a&>1==&a(Y&]XC[X& 7C0>;CšY>(;&7C0>;CšY>17&>(&]XC[X&\/;>C[Y=/;&\X/;6/[ap&ša&a1/;p&ša&`(=Y61p&/97&]X1;1&>X1&\C==0& [/61&^;(6pœ&>X/>&X1&[(Y=7&›C6617C/>1=a&=((Ÿ&/>&`(=Y61&/97&71>1[>&\/>>1;90&]C>X&>X1&7/>/&>X/>&]1& [Y;;19>=a&X/`1pœ&/97&>X/>&X1&X/0&>X/>&7/>/&›^(;&1`1;a&>;/90/[>C(9&C9&>X1&L9C>17&S>/>10)œ&& ˆl&/>&R)&& WX19&/0Ÿ17&›ª]«X/>T0&>X1&6(0>&C6\(;>/9>&>XC9Z&>X/>&C>&X/0&0X(]9&a(Ypœ&#;)&%1N=/9[&;1\=C173&& ›IX/>&>X1&0>(;C10&>X/>&a(YT`1&X1/;7&^;(6&0(61&(^&>X1&$Q:&C9`10>CZ/>C̀1&/Z19>0&[(9[1;9C9Z&>X1& =/;Z1&`(=Y610&(^&\C==0&Z(C9Z&C9>(&[1;>/C9&\/;>0&(^&(Y;&[(Y9>;a&/;1/&/š0(=Y>1=a&>;Y1)œ&& ˆl&/>&4)&&IX1& ;1\(;>1;&>X19&0>/>17p&›ª(«91&(^&>X(01&0>(;C10&[(9[1;917&O1;6C>p&W10>&UC;ZC9C/p&/&>(]9&(^&£Y0>&-,,& \1(\=1p&]X1;1&9C91&6C==C(9&(\C(C7&\C==0&]1;1&71=C̀1;17&C9&£Y0>&>](&a1/;0&>(&/&0C9Z=1&\X/;6/[apœ& /97&/0Ÿ17&]X1>X1;&›>X1&[(6\/9C10&ªX/7«&/[[100&>(&>XC0&C9^(;6/>C(9)œ&& ˆl&&#;)&%1N=/9[& 2,& Case: 1:17-md-02804-DAP Doc #: 1225-2 Filed: 01/04/19 16 of 26. PageID #: 29661 ;10\(97173&&›IXC0&]/0&>X1C;&7/>/)œ&& ˆl&&H>&C0&(š`C(Y0&>X/>&>X1&:J.KS&7/>/&^(;617&>X1&š/0C0&^(;& #;)&%1N=/9[T0&0>/>1619>0®&>X/>&>X1&0>/>1619>0&]1;1&6/71&^(;&/9&Y9/Y>X(;C§17&\Y;\(01&rol…lp&9(>&>(& ›617C/>1p&01>>=1p&\;(01[Y>1&(;&71^197œ&>X1&=C>CZ/>C(9p&/97&9(>&^(;&›=/]&19^(;[1619>&\Y;\(010œs®& /97&>X/>&>X1a&]1;1&[(66Y9C[/>17&>(&>X1&617C/&/97&>X1&\Yš=C[&]C>X(Y>&\;C(;&/\\;(`/=&(^&>XC0& .(Y;>)&&& #;)&#((;1&/97&#;)&$1WC91&=CŸ1]C01&Y017&>X1&:J.KS&7/>/&^(;&Y9/Y>X(;C§17&\Y;\(010& /97&6/71&0>/>1619>0&/š(Y>&C>&>(&>X1&617C/&/97&>X1&\Yš=C[&]C>X(Y>&\;C(;&.(Y;>&/\\;(`/=)&& #;)&#((;1&(\C917&>X/>&›>X1&:J.KS&7/>/&ªZ/`1«&XC6&>X1&/66Y9C>C(9&X1&91170&>(&716(=C0X&>X1& (\C(C7&C97Y0>;aT0&/;ZY619>pœ&/97&/7717&>X/>3&&›H^&a(YT`1&Z(>&]/=ŸC9Z&/;(Y97&01901&/97&a(Y&[/;1p& a(YT;1&Z(C9Z&>(&[X1[Ÿ&š1^(;1&a(Y&0197&9C91&6C==C(9&\C==0&>(&/&=C>>=1p&šC>>a&[(Y9>a&C9&W10>&UC;ZC9C/& (;&#C00C00C\\C&(;&%(YC0C/9/&(;&KXC()œ&& ˆl&/>&4p&+)&&#;)&$1WC91&\;([=/C617&>X1&:J.KS&7/>/& ›0X([ŸC9Zpœ&/97&/001;>17&>X/>&›ª/«9a(91&]X(&]/0&=((ŸC9Z&/>&>X(01&9Y6š1;0p&/0&>X(01&6C77=1619& ]1;1p&/0&>X101&7C0>;CšY>(;0&]1;1p&[=1/;=ap&[=1/;=a&0X(Y=7T`1&0119&>X/>&0(61>XC9Z&]/0&7;/6/>C[/==a& ];(9Z)œ&& ˆlj/>&4)&H9&6/ŸC9Z&>X101&0>/>1619>0p&#;)&$1WC91&]/0&]1==&/]/;1&(^&>XC0&.(Y;>T0& ;10>;C[>C(90&(9&7C0[=(0Y;1¥Z(C9Z&0(&^/;&/0&>(&/76C>&>X/>&X1&]/0&›9(>&/==(]17&>(&>/=Ÿ&/š(Y>&>X1& 0\1[C^C[0)œ&& ˆl&&NY>&>XC0&.(Y;>T0&\;(>1[>C̀1&(;71;&C0&ša&9(&61/90&=C6C>17&>(&›0\1[C^C[0œ&/š(Y>&>X1& :J.KS&7/>/p&/0&>X1&\=/C9&>1¢>&(^&>X1&(;71;&6/Ÿ10&[=1/;)&&€……j‰…i…gf††v&Q.M&2R4)&&H>&[/>1Z(;C[/==a& \;(XCšC>0&[(`1;17&\/;>C10&^;(6&Y0C9Z&[(9^C719>C/=&:J.KS&7/>/&^(;&/9a&\Y;\(01&(>X1;&>X/9&>X(01& 01>&^(;>X&C9&>X1&(;71;&C>01=^¥9/61=a&=C>CZ/>C(9&(;&=/]&19^(;[1619>)&& ˆl&/>&_)&&:97&C>&š/;0&>X(01& \1;0(90&^;(6&[(66Y9C[/>C9Z&>X1&7/>/&>(&>X1&\Yš=C[&(;&>X1&617C/&›C9&/9a&]/a&(;&^(;6œ&]C>X(Y>& >XC0&.(Y;>T0&\;C(;&/\\;(`/=)&& ˆl&/>&-)& #;)&#((;1&/=0(&`C(=/>17&/9(>X1;&.(Y;>&(;71;&ša&[(6619>C9Z&(9&>X1&0>/>Y0&(^&01>>=1619>& 7C0[Y00C(90)&&:^>1;&9Y61;(Y0&\;100&;1\(;>0&C9/[[Y;/>1=a&;1\(;>17&(9&>X1&01>>=1619>&91Z(>C/>C(90p& 22& Case: 1:17-md-02804-DAP Doc #: 1225-2 Filed: 01/04/19 17 of 26. PageID #: 29662 >XC0&.(Y;>&(;71;17&›/==&\/;>C[C\/9>0œ&C9&>X1&91Z(>C/>C(90p&›/97&/==&(>X1;&[(Y901=&/97&\/;>C10&]X(& /;1&[(90Y=>17œ&/š(Y>&>X(01&91Z(>C/>C(90p&>(&›6/C9>/C9&0>;C[>&[(9^C719>C/=C>a&/0&>(&>X1&[(9>19>0&(^& >X(01&7C0[Y00C(90)œ&&Q.M&22R&/>&2)&&H>&/=0(&7C;1[>17&>X/>&›9(š(7a&C0&>(&7C0[=(01&>(&>X1&617C/&(;&/9a& (Y>0C71&\/;>a&>X1&[(9>19>0&(^&>X1&7C0[Y00C(90p&(;&\;(`C71&>X1&617C/&/00100619>0&(;&[(6619>/;a& ;1Z/;7C9Z&>X(01&7C0[Y00C(90)œ&& ˆl&&#;)&#((;1T0&0YZZ10>C(9&>X/>&\=/C9>C^^0T&[(Y901=&/;1&›/&=(9Z& ]/a&^;(6&[(9`C9[C9Z&>X1&7;YZ&C97Y0>;aœ&>(&\/a&>X16&6(91ap&Q¢)&2&/>&qp&C0&/&[=1/;&`C(=/>C(9&(^&>XC0& (;71;)&&:97&>XC0&C0&9(>&1`19&>X1&^C;0>&>C61&\=/C9>C^^0T&[(Y901=&`C(=/>17&>X/>&(;71;&ša&7C0[=(0C9Z& C9^(;6/>C(9&/š(Y>&>X1&[(9^C719>C/=&01>>=1619>&91Z(>C/>C(90&>(&>X1&\;100)&&& 222± 86 8 6 954968156 3 496781 32 1768946¾89981345±6 WX19&/&=/]a1;&`C(=/>10&/&;Y=1&(^&\;(^100C(9/=&[(97Y[>&(;&[(Y;>&(;71;p&0/9[>C(90&/;1& /\\;(\;C/>1p&/97&C97117&91[100/;ap&›9(>&61;1=a&>(&\19/=C§1&>X(01&]X(01&[(97Y[>&6/a&š1&711617& >(&]/;;/9>&0Y[X&/&0/9[>C(9p&šY>&>(&71>1;&>X(01&]X(&6CZX>&š1&>16\>17&>(&0Y[X&[(97Y[>&C9&>X1& /š019[1&(^&0Y[X&/&71>1;;19>)œ&&Œft–†j‡h—…vjz…f‰n…jkljx…tlj‡h—…vj{†n“p&-*4&L)S)&R_Vp&R-_& r2V4Rs®&……jf†hj%([/=&JY=1&+_)4ršs&r/Y>X(;C§C9Z&›0Y[X&7C0[C\=C9/;a&/[>C(9&/0&>X1&[C;[Y60>/9[10& ]/;;/9>œs)&&›ªI«X1&X/;6&]XC[X&](Y=7&;10Y=>&]1;1&ª/>>(;91a0«&>(&Z(&Y9\Y9C0X17&](Y=7&š1&>X1& Y90\(Ÿ19&197(;01619>&(^&^=/Z;/9>&7C0;1Z/;7&^(;&>XC0&.(Y;>T0&(;71;0œ&/97&;Y=10&Z(`1;9C9Z&>X1& =1Z/=&\;(^100C(9)&&˜fn†…vjkljiot…ˆj™~…gftoi‰j{hlp&R,R&M)&SY\\)&q*,p&q*4&rQ)$)&#C[X)&2V+qs)&& 8± 3¿G6 ÀÁÂÃ67¿ÀÁÄÅ62ccÁG6E6 EF6 ÂÅGÂ6@EÆÅEÃÇÆF67ÃÂÇÈÃ6 ÀÉÊÄÇEÆÈG6ËÇÿ6 ¿ÇÀ69ÁÄG6ÀÌ6 ÂÀÌGccÇÀÆEÄ6 ÀÆÅÁÈÃ6ͱα6 ›ªI«X1&;CZX>&>(&/&^/C;&>;C/=&)&)&)&C0&(91&(^&(Y;&6(0>&[X1;C0X17&`/=Y10p&/97&/&>;C/=&£Y7Z1&0X(Y=7& X/`1&>X1&/Y>X(;C>a&>(&/7(\>&;1/0(9/š=1&61/0Y;10&>(&/`(C7&C9£Y;apœ&C9[=Y7C9Z&ša&C00YC9Z&/&›Z/Z& (;71;œ&\;(XCšC>C9Z&C6\;(\1;&[(66Y9C[/>C(90&š1>]119&\=/C9>C^^0T&[(Y901=&/97&>X1&\;100)&&efghiyj *,2_&W%&2*2*2q2Rp&/>&²2&r19>1;C9Z&Z/Z&(;71;&>(&/77;100&[(Y901=T0&C6\;(\1;&1¢>;/£Y7C[C/=& 0>/>1619>0s)&&SY[X&(;71;0&\;(>1[>&>X1&C9>1Z;C>a&/97&^/C;9100&(^&>X1&£Y7C[C/=&0a0>16&/97&/;1&/& 2*& Case: 1:17-md-02804-DAP Doc #: 1225-2 Filed: 01/04/19 18 of 26. PageID #: 29663 [(66(9&/97&/\\;(\;C/>1&61/90&(^&;17;100C9Z&`C(=/>C(90&(^&1>XC[/=&;Y=10&/Z/C90>&1¢>;/£Y7C[C/=& 0>/>1619>0)&& ˆl&&IX1a&›^/==&]C>XC9&>X1&.(Y;>T0&\;1;(Z/>C̀1&>(&6/C9>/C9&/\\;(\;C/>1&71[(;Y6&C9&>X1& /76C9C0>;/>C(9&(^&£Y0>C[1&/97&>(&\;(>1[>&>X1&;CZX>0&(^&>X1&=C>CZ/9>0&^;(6&\;1£Y7C[1)œ&& ˆlq IX1;1&[/9&š1&9(&[=1/;1;&[C;[Y60>/9[10&£Y0>C^aC9Z&19>;a&(^&/&Z/Z&(;71;&>X/9&>X(01&\;1019>17& X1;1)&&IX1&;1[19>& ¡jxoint…j01Z619>&C9`(=`17&]C==^Y=&`C(=/>C(90&(^&>X1&KXC(&JY=10&(^& <;(^100C(9/=&J10\(90CšC=C>ap&(9&9/>C(9/=&>1=1`C0C(9p&ša&6Y=>C\=1&(^^C[1;0&(^&>XC0&.(Y;>¥C9[=Y7C9Z& /&^(;61;&#C00C00C\\C&:>>(;91a&P191;/=&r/97&01=^5\;([=/C617&›Y9(^^C[C/=&[(66/97C9Z&(^^C[1;&(^& >X1&/;6a&>X/>T0&/>>/[ŸC9Z&>X1&(\C(C7&C97Y0>;apœ&Q¢)&2&/>&_sp&/97&>X1&[Y;;19>&KXC(&:>>(;91a&P191;/=& r/97&P(`1;9(;51=1[>s¥^(;&>X1&0>/>17&\Y;\(01&(^&>;aC9Z&>XC0&[/01&C9&>X1&›[(Y;>&(^&\Yš=C[&(\C9C(9œ& ;/>X1;&>X/9&C9&/&[(Y;>&(^&=/])&&IX1&>X;1/>&>X/>&>X1&71^197/9>0&]C==&9(>&š1&/š=1&>(&;1[1C̀1&/&^/C;&>;C/=& C9&KXC(p&(;&#C00C00C\\Cp&(;&/9a]X1;1&1=01&C9&>X1&[(Y9>;a&C0&;1/=p&/97&6Y=>C\=C10&1¢\(919>C/==a&]C>X& 1/[X&C6\;(\1;&0>/>1619>&>(&>X1&\;100)&& :&Z/Z&(;71;&C0&10019>C/=&>(&\;101;`1&]X/>1`1;&[/9&š1&0/=`/Z17&(^&71^197/9>0T&;CZX>0&>(&7Y1& \;([100&/97&/&^/C;&/7£Y7C[/>C(9&(^&>X1&[=/C60&/001;>17&/Z/C90>&>X16)R&&'(&=1001;p&/=>1;9/>C̀1& ;1617a&[(Y=7&\;(>1[>&>X101&C9>1;10>0p&10\1[C/==a&C9&=CZX>&(^&>X1&\=/C9>C^^0T&0>/>17&C9>19>&>(&Y01&>X1& 617C/&›>(&C9^=Y19[1&\Yš=C[&\1;[1\>C(9&(^&ª7«1^197/9>0pœ&efghip&*,2_&W%&2*2*2q2Rp&/>&²*p&/97& >X1&^/[>&>X/>&>XC0&]/0&9(>&>X1&^C;0>&>C61&\=/C9>C^^0T&[(Y901=&Y017&>X1&617C/&>(&>1==&>X1C;&(9150C717& 0>(;a&(^&>X1&[/01)&&€……j‘…ito†…p&q,2&L)S)&/>&2,4q&r1`19&›ª1«¢>190C̀1&khogjˆog…&6/a&9(>&š1&/š=1&>(& ^C=>1;&(Y>&/==&(^&>X1&1^^1[>0&(^&\;1>;C/=&\Yš=C[C>aœs)&&:š019>&C9>1;`19>C(9&ša&>XC0&.(Y;>p&C>&0Y;1=a&]C==& 9(>&š1&>X1&=/0>)&& q&›H ^&>X1;1&]1;1&9(&ª=C6C>0&(9&/&=/]a1;T0&/šC=C>a&>(&6/Ÿ1&1¢>;/£Y7C[C/=&0>/>1619>0«p&>X1&;10Y=>& ](Y=7&š1&>X1&\;/[>C[/=&9Y==C^C[/>C(9&(^&>X1&\;(>1[>C̀1&1^^1[>&(^&>X1&;Y=10&(^&^(;190C[&71[(;Y6&/97& >X1&1¢[=Y0C(9/;a&;Y=10&(^&1`C719[1)œ&&K^^C[C/=&.(6619>&>(&KXC(&J)&<;(^)&.(97)&_)Rp&/>&ª2«)& R&I(&š1&[= 1/;p&71^197/9>0T&;CZX>0&6/a&]1==&X/`1&š119&C;;1>;C1`/š=a&X/;617&ša&>X1&š1X/`C(;&(^& \=/C9>C^^0T&[(Y901=p&/97&71^197/9>0&;101;`1&/==&;CZX>0&C9&>XC0&;1Z/;7)&&&& 2_& Case: 1:17-md-02804-DAP Doc #: 1225-2 Filed: 01/04/19 19 of 26. PageID #: 29664 IX1&Z/Z&(;71;&0X(Y=7&0\1[C^C[/==a&š/;&\=/C9>C^^0T&[(Y901=&^;(6&/9a&/97&/==&[(97Y[>&>X/>& ](Y=7&`C(=/>1&KXC(&JY=1&(^&<;(^100C(9/=&J10\(90CšC=C>a&_)Rp&C9[=Y7C9Z&šY>&9(>&=C6C>17&>(&6/ŸC9Z& 1¢>;/£Y7C[C/=&0>/>1619>0&/š(Y>&›ª>«X1&[X/;/[>1;p&[;17CšC=C>ap&(;&;1\Y>/>C(9&(^&/&\/;>apœ&›ª>«X1& 0>;19Z>X0&(;&]1/Ÿ910010&(^&/9a&\/;>aT0&[/01pœ&›ª/«9a&C9^(;6/>C(9&>X1&/>>(;91a0&Ÿ9(]&(;& ;1/0(9/š=a&0X(Y=7&Ÿ9(]&C0&=CŸ1=a&>(&š1&C9/76C00Cš=1&/0&1`C719[1&/97&](Y=7&[;1/>1&/&0Yš0>/9>C/=& ;C0Ÿ&(^&\;1£Y7C[1&C^&7C0[=(017pœ&mh…p&*,2R&W%&V2,42_4p&/>&²Rp&(;&›[(9^C719>C/=&C9^(;6/>C(9œ& 0Yš£1[>&>(&\;(>1[>C̀1&(;71;0)&&iot…ˆj€tft…jklj”hn“gotop&_,4&M)&SY\\)&*7&+V2p&V,*&rQ)$)&#C[X)& *,,-s)&&& D± 3¿Çc6 ÀÁÂÃ67¿ÀÁÄÅ6 ÂÅGÂ69GÄÇGÌ6 ÀÂ6 ÄEÇÆÃÇÌÌc?6 ÀÁÆcGÄ?c6 ÇÀÄEÃÇÀÆc6ÀÌ62Ãc6 ÂGÏÇÀÁc6 ÂÅGÂc±6 :0&1¢\=/C917&/š(`1p&\=/C9>C^^0T&[(Y901=&71=Cš1;/>1=a&^=(Y>17&>XC0&.(Y;>T0&(;71;0&>X/>&>X1& :J.KS&7/>/&š1&Y017&(9=a&^(;&\Y;\(010&(^&›>XC0&=C>CZ/>C(9œ&/97&›=/]&19^(;[1619>pœ&……yj…l‰lpQ.M& 2R4&/>&_®&Q.M&*__&/>&**®&Q.M&_V4&/>&_p&/97&›9(>&š1&[(66Y9C[/>17&>(&>X1&\Yš=C[&(;&617C/&oijfivj ƒfvjhgj‹hg}&]C>X(Y>&\;C(;&/\\;(`/=&(^&>X1&.(Y;>pœ&Q.M&2R4&/>&-&r16\X/0C0&/7717s®&/0&]1==&/0&>XC0& .(Y;>T0&(;71;&>X/>&>X1&\/;>C10&›6/C9>/C9&0>;C[>&[(9^C719>C/=C>a&/0&>(&>X1&[(9>19>0&(^&ª01>>=1619>«& 7C0[Y00C(90œ&/97&9(>&›7C0[=(01&>(&>X1&617C/&(;&/9a&(Y>0C71&\/;>a&>X1&[(9>19>0&(^&>X1&7C0[Y00C(90p& (;&\;(`C71&>X1&617C/&/00100619>0&(;&[(6619>/;a&;1Z/;7C9Z&>X(01&7C0[Y00C(90pœ&Q.M&22R&/>&2)&& WXC=1&>X1&7C0[=(0Y;10&\=/C9>C^^0T&[(Y901=&6/71&]1;1&/>&/&XCZX&=1`1=&(^&Z191;/=C>ap&>X1a&/;1& 91`1;>X1=100&7101;`C9Z&(^&/9&/\\;(\;C/>1&;1617a&š1[/Y01&>X1a&]1;1&\/;>&(^&/&š;(/71;&\/>>1;9&(^& 7C0;10\1[>&/97&71=Cš1;/>1&7C0;1Z/;7&^(;&>X1&;CZX>0&(^&>X1&71^197/9>0&/97&>X1&C9>1Z;C>a&(^&>X1& £Y7C[C/=&\;([100)& H9&0C6C=/;&[C;[Y60>/9[10p&[(Y;>0&X/`1&C6\(017&/&`/;C1>a&(^&0/9[>C(90)&&H9&mhg…ttjklj {hnitvjh‹jŒffnp&^(;&1¢/6\=1p&>X1&[(Y;>&X1=7&/&9(95\/;>a&C9&[(9>16\>&/97&;1¬YC;17&XC6&>(&\/a&/& ^C91&^(;&`C(=/>C9Z&/&[(Y;>&(;71;&/97&7C0[=(0C9Z&C9^(;6/>C(9&/š(Y>&/&[(9^C719>C/=&;1\(;>&>(&/&=([/=& 2-& Case: 1:17-md-02804-DAP Doc #: 1225-2 Filed: 01/04/19 20 of 26. PageID #: 29665 91]0&\;(Z;/6)&&Q`19&>X(YZX&(9=a&/&›^1]&71>/C=0œ&]1;1&7C0[=(017p&/97&1`19&>X(YZX&>X1&[(Y;>&7C7& 9(>&>XC9Ÿ&X1&/[>17&]C==^Y==ap&>X1&›`1;a&\Yš=C[&6/991;œ&(^&>X1&7C0[=(0Y;1&/97&>X1&9117&>(&190Y;1& ›^Y>Y;1&[(6\=C/9[1œ&ša&>X/>&9(95\/;>a&/97&(>X1;&1=1[>17&(^^C[C/=0&]C>X&/[[100&>(&>X1&;1\(;>&/97& ]C>X&/9&C9[19>C̀1&>(&›0/>C0^a&>X1C;&[(90>C>Y19>0pœ&]/;;/9>17&/&;1617a)&&'()&.U&2,5,2*q+&:$Sp& *,2*&W%&*,4RV22p&/>&²2,522&rQ)$)'))&ŽY91&4p&*,2*s)&&:&[(6\/;/š=1&0/9[>C(9&](Y=7&š1& /\\;(\;C/>1&X1;1&/97&C0&]1==&]C>XC9&>XC0&.(Y;>T0&/Y>X(;C>a)&&€……j‚ghƒijklj„…††…g}ft…j‡h†ˆoi‰j ztˆlp&'()&*3225[`522**p&*,2q&W%&-4-*R+Rp&/>&²R&rS)$)&KXC(&:YZ)&22p&*,2qs&r`C(=/>C(9&(^& \;(>1[>C̀1&(;71;&š/0C0&^(;&C6\(0C9Z&JY=1&_4ršsr*s&0/9[>C(90s®&o…†ˆj„ng‹j€eyj iljklj€~hgtj {hitlj‘ghn~yjzz{p&'()&23,R&.U&*R*-p&*,,4&W%&--2*+qqp&/>&²-5R&r')$)&KXC(&$1[)&2*p&*,,4s& r0/61s®&”ih•jklj{otvjh‹jg…ihp&'()&232-5[`5,,4VVp&*,2R&W%&2,R-42V+p&/>&²25_&rQ)$)&./=)&ŽY91& *p&*,2Rs&r`C(=/>C(9&(^&\;(>1[>C̀1&(;71;&š/0C0&^(;&X(=7C9Z&/>>(;91a0&C9&[(9>16\>&/97&C6\(0C9Z& 0/9[>C(90&Y971;&[(Y;>T0&C9X1;19>&/Y>X(;C>as®&xmhif†ˆjklj{hh~…gj„og…j’jŠn““…gj{hlp&'()&+3,25 [`52_,Rp&*,,q&W%&*+2,4,4p&/>&²25_&r#)$)&M=/)&K[>)&*4p&*,,qs&r0/61s)&&& $1^197/9>0&/=0(&;101;`1&>X1&;CZX>&>(&/;ZY1&>X/>&/&\/;>a&]X(01&[(Y901=&C6\;(\1;=a& 7C0[=(017&C9^(;6/>C(9&C9&`C(=/>C(9&(^&[(Y;>&(;71;0&0X(Y=7&9(>&š1&\1;6C>>17&>(&;1=a&(9&>X/>& C9^(;6/>C(9&/>&>;C/=)&&{‹lxfiijkljiokljh‹j{oioiiftop&+*-&M)&SY\\)&22V,&rS)$)&KXC(&2VV_s& r0/9[>C(9C9Z&/&Y9C̀1;0C>a&/97&C>0&/>>(;91a0&]X(&X/7&C6\;(\1;=a&7C0[=(017&>X1&\=/C9>C^^T0&\;C̀/>1& 617C[/=&7/>/&ša&1¢[=Y7C9Z&>X/>&7/>/&^;(6&>;C/=p&1`19&>X(YZX&C>&]/0&;1=1`/9>&>(&>X1&C00Y1&(^& 7/6/Z10&/97&>(&>X1&\=/C9>C^^T0&[;17CšC=C>asp&f‹‹–ˆy&2q*&M)J)$)&22Vp&2*,q&rS)$)&KXC(&2VV_sp&f‹‹–ˆp& 22-&M)_7&22++&rR>X&.C;)&2VV4s®&……jf†hjM17)&J)&.C̀)&<)&_4ršsr*sr:srCCs&r/Y>X(;C§C9Z&(;71;& \;1[=Y7C9Z&\/;>a&^;(6&›C9>;(7Y[C9Z&710CZ9/>17&6/>>1;0&C9>(&1`C719[1œs)&&& 2q& Case: 1:17-md-02804-DAP Doc #: 1225-2 Filed: 01/04/19 21 of 26. PageID #: 29666 ± 3¿Çc6 ÀÁÂÃ67¿ÀÁÄÅ68ËEÂÅ65GÌGÆÅEÆÃc63¿GÇÂ68ÃÃÀÂÆGÐc?6 GGc6EÆÅ6 ÀcÃc6 2ÆÈÁÂÂGÅ68c6869GcÁÄÃ6 Ì6 ÄEÇÆÃÇÌÌc?6 ÀÁÆcGÄ?c6@ÇcÈÀÆÅÁÈñ6 IXC0&.(Y;>&/=0(&0X(Y=7&/]/;7&71^197/9>0&>X1&/>>(;91a0T&^110&/97&[(0>0&C9[Y;;17&/0&/&;10Y=>& (^&\=/C9>C^^0T&[(Y901=T0&`C(=/>C(90&(^&>X1&;Y=10&(^&\;(^100C(9/=&[(97Y[>&/97&>XC0&.(Y;>T0&(;71;0)&&:0& >X1&SY\;161&.(Y;>&;1[19>=a&;1/^^C;617p&>XC0&.(Y;>&X/0&>X1&C9X1;19>&/Y>X(;C>a&>(&^/0XC(9& /\\;(\;C/>1&0/9[>C(90&^(;&=C>CZ/>C(9&6C0[(97Y[>p&C9[=Y7C9Z&>X1&›/00100619>&(^&/>>(;91aT0&^110&)&)&)& >(&;1C6šY;01&=1Z/=&^110&/97&[(0>0&C9[Y;;17&ša&>X1&(>X1;&0C71œ&/0&/&;10Y=>&(^&>X1&6C0[(97Y[>)&& ‘hhˆv…fgj„og…j’jŠn““…gj{hljklj‡f…‰…gp&2_4&S)&.>)&224+p&22+R&r*,24s&rC9>1;9/=&[C>/>C(90&/97& ¬Y(>/>C(9&6/;Ÿ0&(6C>>17s)&&.(Y;>0&X/`1&/]/;717&^110&/97&[(0>0&]X19&/&\/;>a&7C0[=(010& [(9^C719>C/=&C9^(;6/>C(9&C9&`C(=/>C(9&(^&/&[(Y;>&(;71;p&1`19&]X19¥Y9=CŸ1&X1;1¥>X1&7C0[=(0Y;1& ]/0&C9/7`1;>19>)&&€……yj…l‰lp&€}otuj’jn††…gyj˜leljklj{hh~…gj„og…j’jŠn““…gj{hlp&R+q&M)_7&-+Rp& -V,5V2&rq>X&.C;)&*,2*s&r/^^C;6C9Z&/]/;7&(^&/>>(;91aT0&^110&^(;&C9/7`1;>19>&7C0[=(0Y;1s®&‚ghƒiyj *,2q&W%&-4-*R+Rp&/>&²R&r/]/;7C9Z&/>>(;91aT0&^110s®&……jf†hjM17)&J)&.C̀)&<)&_4ršsr*sr.s&r›[(Y;>& 6Y0>&(;71;&)&)&)&ª>X1&\/a619>&(^«&;1/0(9/š=1&1¢\19010p&C9[=Y7C9Z&/>>(;91aT0&^110p&[/Y017&ša&>X1& ^/C=Y;1&ª>(&[(6\=a&]C>X&/&7C0[(`1;a&(;71;«p&Y9=100&>X1&^/C=Y;1&]/0&0Yš0>/9>C/==a&£Y0>C^C17&(;&(>X1;& [C;[Y60>/9[10&6/Ÿ1&/9&/]/;7&(^&1¢\19010&Y9£Y0>œs)&&81;1p&\=/C9>C^^0T&[(Y901=T0&C9>19>C(9/=&1^^(;>0& >(&>/C9>&>X1&\;([117C9Z0&/97&71\;C̀1&71^197/9>0&(^&/&^/C;&/7£Y7C[/>C(9&>X;(YZX&>X1C;&C6\;(\1;& 1¢>;/£Y7C[C/=&0>/>1619>0&/97&7C0[=(0Y;10&6(;1&>X/9&£Y0>C^C10&/9&/]/;7&(^&^110)4 5± 3¿Çc6 ÀÁÂÃ6@ÁcÃ69GÌGÂ68ÄÄGFEÃÇÀÆc6ÀÌ6 ÂÀÌGccÇÀÆEÄ6@ÇcÈÀÆÅÁÈÃ6ÃÀ6ÿG6 ÀÁÂÃ?c6 ÀÉÉÇÃÃGG6ÀÆ6 ÀÉÊÄEÇÆÃc6EÆÅ6 ÀÄÇÈÐ6 ÀÉÊÄÇEÆÈG±6 Q¢[1\>&C9&[C;[Y60>/9[10&9(>&\;1019>&X1;1p&%([/=&JY=1&+_)4r7s&;1¬YC;10&>X/>&]X19&>XC0& .(Y;>&š1[(610&/]/;1&(^&/&`C(=/>C(9&(;&\(>19>C/=&`C(=/>C(9&(^&>X1&KXC(&JY=10&(^&<;(^100C(9/=& 4&H 9&^/[>p&>X1&1¢>;/£Y7C[C/=&0>/>1619>0&>/;Z1>17&/>&KXC(&ša&KXC(T0&XCZX10>5;/9ŸC9Z&=/]a1;&/97& C9[(6C9Z&Z(`1;9(;&C9&>XC0& ¡jxoint…j1\C0(71&r/97&1=01]X1;1s&]1;1&XCZX=a&\;1£Y7C[C/=&/97& >X;1/>19&>X1&`1;a&`C/šC=C>a&(^&KXC(&/0&/&0YC>/š=1&`19Y1)&&$1^197/9>0&;101;`1&>X1&;CZX>&>(&š;C9Z&/& [X/9Z1&(^&`19Y1&6(>C(9p&/97(;&/0Ÿ&>X1&.(Y;>&>(&/7£Y0>&>;C/=&0[X17Y=10p&/>&/9&/\\;(\;C/>1&>C61)&&& 2R& Case: 1:17-md-02804-DAP Doc #: 1225-2 Filed: 01/04/19 22 of 26. PageID #: 29667 J10\(90CšC=C>a&ša&/&=/]a1;&/76C>>17&>(&\;/[>C[1&š1^(;1&>XC0&.(Y;>p&>X1&6/>>1;&6Y0>&š1&;1^1;;17&>(& >X1&.(Y;>T0&.(66C>>11&(9&.(6\=/C9>0&/97&<(=C[a&.(6\=C/9[1p&]C>X&9(>C^C[/>C(9&>(&>X1&.=1;Ÿ&(^& .(Y;>p&›^(;&C9`10>CZ/>C(9&/97&>X1&\;(01[Y>C(9&(^&/&^(;6/=&7C0[C\=C9/;a&\;([117C9Z&(;&>X1& ^(;6Y=/>C(9&(^&0Y[X&(>X1;&;1[(66197/>C(9&/0&C0&/\\;(\;C/>1)œ&&IXC0&\;([17Y;1&C0&6/97/>(;ap&9(>& 7C0[;1>C(9/;a)&&:>&/&6C9C6Y6p&#;)&#((;1p&#;)&$1WC91p&/97&#;)&%1N=/9[&6Y0>&š1&;1^1;;17&>(& >XC0&.(66C>>11&C9&=CZX>&(^&>X1C;&[=1/;&`C(=/>C(90&(^&KXC(&JY=1&(^&<;(^100C(9/=&J10\(90CšC=C>a&_)R) IXC0&.(Y;>&/=0(&0X(Y=7&71>1;6C91&]X1>X1;&/77C>C(9/=&;1^1;;/=0&/;1&/\\;(\;C/>1)&&:0&9(>17& /š(`1p&>X1&`C71(&(^&>X1& ¡jxoint…&01Z619>&[(9^C;60&>X/>&9Y61;(Y0&(>X1;&=/]a1;0&^(;&>X1& \=/C9>C^^0&]1;1&/]/;1&(^&/97&C9`(=`17&C9&>X1&[/6\/CZ9&>(&7C0016C9/>1&\=/C9>C^^0T&(9150C717&`C1]& (^&>X1&[/01&>(&>X1&\;100&/97&>X1&\Yš=C[)&&€……jf†h&Q¢)&2&/>&_&r9(>C9Z&>X/>&›/š(Y>&/&7(§19&=/]a1;0& ^;(6&/==&/;(Y97&>X1&[(Y9>;aœ&]1;1&Z/>X1;17&/>&#;)&#((;1T0&›[(66/97&[19>1;œ&(9&>X1&7/a& ¡j xoint…&`C0C>17s)&&IXC0&.(Y;>&0X(Y=7&(;71;&#;)&#((;1p&#;)&$1WC91&/97&#;)&%1N=/9[&>(&C719>C^a& /==&[(Y901=&]X(&]1;1&\;1019>&^(;&>X1&>/\C9Z&(^&>X1& ¡jxoint…j01Z619>&(;&(>X1;]C01&Ÿ9(]C9Z=a& /00C0>17p&C97Y[17p&(;&\/;>C[C\/>17&C9&>X1&1^^(;>&C9&/9a&]/a)&&€……&KXC(&J)&<;(^)&.(97)&+)-) 1 072 16 M(;&>X1&^(;1Z(C9Z&;1/0(90p&>XC0&.(Y;>&0X(Y=7&Z;/9>&>XC0&6(>C(9&/97&(;71;&>X1&;1=C1^&01>& ^(;>X&š1=(]&/97&/==&(>X1;&;1=C1^&>X1&.(Y;>&71160&91[100/;a3&& r2s& #;)&#((;1p&#;)&$1WC91p&/97&#;)&%1N=/9[p&/==&[(Y901=&;1\;1019>C9Z&>X1&\=/C9>C^^0& C9&>XC0&#$%p&/97&/==&>X(01&]X(&X/`1&;1[1C̀17&C9^(;6/>C(9&(;&7([Y619>0&\Y;0Y/9>&>(&>XC0&.(Y;>T0& K;71;0p&0X/==&0>;C[>=a&[(6\=a&]C>X&JY=1&_)R&(^&>X1&KXC(&JY=10&(^&<;(^100C(9/=&.(97Y[>&/97&0X/==& ;1^;/C9&^;(6&6/ŸC9Z&/9a&0>/>1619>0&>(&>X1&617C/&(;&>X1&\Yš=C[&;1=/>C9Z&>(&/9a&(^&>X1&^(==(]C9Z& 0Yš£1[>03&&r/s&>X1&[X/;/[>1;p&[;17CšC=C>ap&(;&;1\Y>/>C(9&(^&/&\/;>a®&ršs&>X1&0>;19Z>X0&(;&]1/Ÿ910010&(^& /9a&\/;>aT0&[/01®&r[s&/9a&C9^(;6/>C(9&>X1&/>>(;91a0&Ÿ9(]&(;&;1/0(9/š=a&0X(Y=7&Ÿ9(]&C0&=CŸ1=a&>(& 24& Case: 1:17-md-02804-DAP Doc #: 1225-2 Filed: 01/04/19 23 of 26. PageID #: 29668 š1&C9/76C00Cš=1&1`C719[1&/97&](Y=7&[;1/>1&/&0Yš0>/9>C/=&;C0Ÿ&(^&\;1£Y7C[1&C^&7C0[=(017®&/97&r7s&>X1& :J.KS&7/>/&(;&/9a&C9^(;6/>C(9&\;(7Y[17&C9&7C0[(`1;a&C9&>XC0&/[>C(9)&&& r*s&& #;)&#((;1p&#;)&$1WC91p&/97&#;)&%1N=/9[&0X/==&š1&/76(9C0X17&^(;&`C(=/>C9Z&>XC0& .(Y;>T0&(;71;0&/97&>X1&.(Y;>&0X(Y=7&C6\(01&/\\;(\;C/>1&0/9[>C(90&>(&71>1;&^Y>Y;1&`C(=/>C(90)& r_s&& #;)&#((;1p&#;)&$1WC91p&/97&#;)&%1N=/9[&0X/==&\/a&>X1&71^197/9>0T&/>>(;91a0T& ^110&/97&[(0>0&C9[Y;;17&/0&/&;10Y=>&(^&>X1C;&6C0[(97Y[>)& r-s&& &>(&%([/=&JY=1&+_)4r7sr2sp&>XC0&6/>>1;&0X/==&š1&;1^1;;17&>(&>X1&.(Y;>T0& .(66C>>11&(9&.(6\=/C9>0&/97&<(=C[a&.(6\=C/9[1p&]C>X&9(>C^C[/>C(9&>(&>X1&.=1;Ÿ&(^&.(Y;>p&^(;& C9`10>CZ/>C(9&/97&>X1&\;(01[Y>C(9&(^&/&^(;6/=&7C0[C\=C9/;a&\;([117C9Z&(;&>X1&^(;6Y=/>C(9&(^&0Y[X& (>X1;&;1[(66197/>C(9&/0&C0&/\\;(\;C/>1)&& rqs&& #;)&#((;1p&#;)&$1WC91p&/97&#;)&%1N=/9[&0X/==&C719>C^a&/==&[(Y901=&]X(&]1;1& \;1019>&^(;&>X1&>/\C9Z&(^&>X1& ¡jxoint…&01Z619>&(;&(>X1;]C01&Ÿ9(]C9Z=a&/00C0>17p&C97Y[17p&(;& \/;>C[C\/>17&C9&>X1&1^^(;>&C9&/9a&]/a)& Ž/9Y/;a&-p&*,2V& J10\1[>^Y==a&0Yš6C>>17p& сÑj{fgh†…j€ljŠ…iˆhijjj ./;(=1&S)&J197(9&& N:OQJ&°&8KSIQI%QJ&%%<&& O1a&I(]1;&2*4&1&*,,,&& .=1`1=/97p&K8&--22-52*2-&& I1=3&r*2Rs&R*25&,*,,&& M/¢3&r*2Rs&RVR5,4-,&& [;197(9Қ/Ÿ1;=/])[(6& {hni…†j‹hgjm…‹…iˆfitjÓiˆhj‡…f†tuj €h†ntohij ilyjÓiˆhj˜ufg}f…ntof†j ilyj ˜fgj˜ufg}f…ntof†yj ilyjfiˆj˜fgj ˜ufg}f…ntof†j{h}~fio…yj iljÔoihgg…t†vj if}…ˆjfj՘fgj˜ufg}f…ntof†j{h}~fio…yj ilj‹Ñ—Ñfj˜fgj˜ufg}f…ntof†j‡h†ˆoi‰yj ilÖ×jj 2+& Case: 1:17-md-02804-DAP Doc #: 1225-2 Filed: 01/04/19 24 of 26. PageID #: 29669 сÑjmhiifjxlj؅†ujj $(99/&#)&W1=[Xp&<).)& rH==C9(C0&N/;&'()&R**R_q*s&& OHJO%:'$&°&Q%%HS&%%<& _,,&'(;>X&%/S/==1& .XC[/Z(p&H==C9(C0&R,Rq-& I1=3&r_2*s&+R*5*-*-& M/¢3&r_2*s&+R*5**,,& 7]1=[XҟC;Ÿ=/97)[(6& {hni…†j‹hgjm…‹…iˆfitje††…g‰fijoifi…yj zz{j‹Ñ—Ñfjetfkoyj ilj‹Ñ—ÑfjØfthij ˜ufg}f…ntof†yj iljfiˆje††…g‰fij˜z{j‹Ñ—Ñfj etfkoj˜z{j сÑj€ufiihijx{†ng…jŠh“…gtj SX/99(9&#[.=Y;1&J(š1;>0& JQQ$&S#HI8&%%<&& IX;11&%(Z/9&S¬Y/;1&& 2424&:;[X&S>;11>p&SYC>1&_2,,&& X)[(6&& {hni…†j‹hgjmotgo“nthgjm…‹…iˆfitj e}…gohng…‚…g‰…ijmgn‰j{hg~hgftohijj {hni…†j‹hgj‡lmlj€}otuj‹hgjtu…j†o}ot…ˆj ~ng~h…jh‹jtuoj}htohij сÑjÓinjxfoio‰ojj Q9Y&#/C9CZC&& WH%%H:#S&°&.K''K%%&%%<& 4*q&I]1=^>X&S>;11>p&')W)&& W/0XC9Z>(9p&$.&*,,,q&& I1=3&r*,*s&-_-5q,,,&& M/¢3&r*,*s&-_-5q,*V&& 16/C9CZCÒ][)[(6& {hni…†j‹hgjm…‹…iˆfitj{fgˆoif†j‡…f†tuyj ilj 2V& Case: 1:17-md-02804-DAP Doc #: 1225-2 Filed: 01/04/19 25 of 26. PageID #: 29670 сÑj„o}htuvjmljwhuihij IC6(>Xa&$)&Ž(X90(9&r,,,RR+Rs& .:UHI.8p&M:#H%K&°&$LJOH'&.K)&%<:& I]19>C1>X&M=((;& 2_,,&Q/0>&'C9>X&S>;11>& .=1`1=/97p&KXC(&--22-& I1=3&&r*2Rs&R*254+R,& M/¢3&&r*2Rs&R*25_-2q& >£(X90(9Ò[/`C>[X)[(6& etthgi…vj‹hgjmohnitjmgn‰jxfgtyj ilj сÑj{ufg†…j{ljzo‹†fiˆjj .X/;=10&.)&%C^=/97&r./=)&N/;&'()&2,+Vq,s& KT#Q%UQ'&°&#QJS&%%<& -,,&S(Y>X&8(\1&S>;11>& %(0&:9Z1=10p&./=C^(;9C/&V,,42& I1=3&r*2_s&-_,5R,,,& M/¢3&r*2_s&-_,5R-,4& [=C^=/97Ò(66)[(6& .hni…†j‹hgjm…‹…iˆfitjwhuihij’jwhuihiÙj wfi…ij˜ufg}f…ntof†yj ilÙjwfi…ij ˜ufg}f…ntofyj iljiїÑfjwfi…ij ˜ufg}f…ntof†yj ilÙjfiˆj™gtuhÚj xŒ…o†Úwfi…ij˜ufg}f…ntof†yj iljiїÑfj wfi…ij˜ufg}f…ntof†yj ilj сÑj‚go…ij„lj™–{hiihgj N;C19&I)&KT.(99(;& :97;1]&Ž)&KT.(99(;& JKC/=&I(]1;& +,,&N(a=0>(9&S>)& N(0>(9p&#:&,*2VV& I1=3&&rR24s&*_q5-Rq,& N;C19)KT.(99(;Ò;(\10Z;/a)[(6& :97;1])KT.(99(;Ò;(\10Z;/a)[(6& {hni…†j‹hgjm…‹…iˆfitjxf††oi—ghˆtjzz{j *,& Case: 1:17-md-02804-DAP Doc #: 1225-2 Filed: 01/04/19 26 of 26. PageID #: 29671 сÑj‘…h‹‹g…vj‡h“fgtjj P1(^^;1a&8(š/;>& .KUH'PIK'&°&NLJ%H'P&%%<& K91&.C>a.19>1;&& +q,&I19>X&S>;11>p&'W& W/0XC9Z>(9p&$.&&*,,,25-VqR& I1=3&&r*,*s&RR*5q*+2& ZX(š/;>Ò[(`)[(6&& {hni…†j‹hgjmotgo“nthgjm…‹…iˆfitjx”…hij {hg~hgftohij сÑjxfg—j€lj{u…‹‹hjj j #/;Ÿ&S)&.X1^^(&& $Q.8QJI&%%<& IX;11&N;a/9>&X1&:61;C[/0& '1]&(;Ÿp&'&2,,_R& I1=3&&r*2*s&RV+5_q,,& #/;Ÿ).X1^^(Ò71[X1;>)[(6& {hni…†j‹hgjm…‹…iˆfitj˜ngˆn…j˜ufg}fjzl˜lyj ˜ngˆn…j˜ufg}fj ilyjfiˆj„u…j˜ngˆn…j g…ˆ…go—j{h}~fivjj *2& Case: Doc 1225-3 Filed: 01/04/19 1 of 9. PageID 29672 Exhibit 1 Case: 1:17-md-02804-DAP Doc #: 1225-3 Filed: 01/04/19 2 of 9. PageID #: 29673 CBS News / CBS Evening News / CBS This Morning / 48 Hours / 60 Minutes / Sunday Morning / Face The Nation / CBSN Originals Episodes Overtime Topics The Team Log In Subscribe RELATED VIDEO NEWSMAKER Opioid C lawsuits bankrup manufa distribu 60 MINUTES The law made B 60 MINUTES What co confide databas Opioid Crisis: The lawsuits that could bankrupt manufacturers and distributors The attorney behind a multibillion-dollar tobacco settlement in 1998 has turned his attention to the opioid epidemic. And he wants drug companies to pay 2018 CORRESPONDENT Dec 16 Bill Whitaker FACEBOOK TWITTER REDDIT Recent Segment The You America Chef Ma Bottura: Pavarott FLIPBOARD Mike Moore says he's, "just a country lawyer from Mississippi." But this country lawyer has engineered two of the most lucrative legal settlements in American history. As Mississippi's attorney general, he engineered the historic 1998 settlement under which Big Tobacco paid billions to address smoking-related health issues. In 2015, he convinced BP to settle multibillion-dollar lawsuits over its huge oil spill in the Gulf of Mexico. Now Mike Moore has taken aim at the manufacturers and distributors of opioid painkillers, claiming they should pay for the epidemic of addiction and death that has swept this nation. As you'll hear in a moment, he has powerful new evidence that he says proves that states like Ohio, among the hardest-hit by the opioid epidemic, should collect billions from all the companies he's suing. Paul McC speaks t Minutes Whisky How a fo officer w betrayin country Case: 1:17-md-02804-DAP Doc #: 1225-3 Filed: 01/04/19 3 of 9. PageID #: 29674 NONINVASIVE colon cancer screening Cologuard performance in repeat testing has not been evaluated. Rx only. is intended for adults 50 ©2018 and older at CologuardCologuard is a registered trademark of Exact Sciences Corporation. Exact Scienc average risk for colorectal2018 cancer. Corporation. All rights reserved. CG-00482-01-July Mike Moore Mike Moore: If we try the Ohio case, if we win a verdict against these manufacturers and distributors there, it could bankrupt them. It'd put them outta business. Bill Whitaker: Truly? These are huge, profitable-Mike Moore: Huge. Bill Whitaker: --wealthy companies. Mike Moore: Well, you know-- they can be as profitable as they want to. But-- Ohio is losing $4 billion or $5 billion a year from the opioid epidemic. And they're losing 5,000 or 6,000 people a year from overdose deaths. So when a jury hears the evidence in this case, they're not gonna award just a couple hundred million dollars. It may be $100 billion. And whoever amongst these companies thinks they can stand up to that? Good luck. Attorney General Mike DeWine: We are hurting now in Ohio. We need help now in Ohio. Ohio's Republican attorney general Mike DeWine, who will be sworn in next month as governor, hired Mike Moore as soon as he decided to file suit against opioid manufacturers and distributors. Attorney General Mike DeWine: They flooded the State of Ohio with these opioid pills that they knew would kill people. Bill Whitaker: They knew would kill people. Attorney General Mike DeWine: If they didn't know it the first couple years, they clearly would've seen it after that. You can't miss it. When one year we had close to a billion-- a billion pain meds prescribed in the state of Ohio, you know, 69 per man, woman, and child in the state. And that lies at the feet of the drug companies. They're the ones who did that. Rx Only. Case: 1:17-md-02804-DAP Doc #: 1225-3 Filed: 01/04/19 4 of 9. PageID #: 29675 Correspondent Bill Whitaker with Attorney General Mike DeWine Ohio is one of four states Mike Moore formally represents, but he's coordinating with 30-plus states that have filed suit, and with many of the local governments, nearly 1,500 cities and counties that also are suing. He is the unofficial commanding officer of the army that's attacking the opioid industry. Bill Whitaker: This is where your war room is located? Mike Moore: That's right. The unlikely "command center" for Moore's legal war is the sleepy town of Grayton Beach on Florida's panhandle. Mike Moore: You know, in a place like this, you're not limited with a bunch of tall buildings, and coats and ties, and that kinda thing. You can think outside the box a little bit. So. When we were in Grayton Beach, about a dozen lawyers from all around the country, some working on state cases, others on local lawsuits, had gathered for all-day strategy sessions, focused on an audacious goal. Mike Moore: Success for me would be that we would find funding to provide treatment for all the 2.5 million opioid-dependent people in this country. That would take many billions of dollars, of course, but remember, Mike Moore has done it before. Mike Moore: Look, when I filed this tobacco case in 1994 there was nobody that thought that we had a chance to win. We showed up for our first hearing, and in our first hearing, so there was three of us there. On the courtroom on the other side they had 68 lawyers. Despite that early mismatch, within four years Moore had all 50 states lined up against Big Tobacco. He did it partly by going to court, but mostly by going public. Mike Moore: A case in court is a case in court, and that's fine. But there's also the court of public opinion. And the court of public opinion is sometime the most powerful court. 60 Minutes played an important and controversial role in the public case against Big Tobacco. Moore was interviewed for a segment that at first, CBS corporate lawyers refused to allow on the air. Mike Moore: We're thinking to ourself, "Look, if 60 Minutes seems to be afraid of these guys for whatever reason, then what about us?" (LAUGH) Case: 1:17-md-02804-DAP Doc #: 1225-3 Filed: 01/04/19 5 of 9. PageID #: 29676 Moore in 1996 60 Minutes finally aired the segment in early 1996 after The Wall Street Journal ran a story featuring the same tobacco industry whistleblower. Bill Whitaker: You said this in that 60 Minutes story, "This industry," talking about this-- the tobacco industry, "in my opinion is an industry… Mike Moore in 1996: …who has perpetrated the biggest fraud on the American public in history. They have lied to the American public for years and years, they've killed millions and millions of people and made a profit on it." Bill Whitaker: Those are pretty strong words. Mike Moore: Well, it-- they were true. Those words were true. Jeffrey Wigand: The big tobacco whistleblower... Jeffrey Wigand: The big tobacco whistleblower Bill Whitaker: And you finally got big tobacco to cry uncle. Mike Moore: That's right. Bill Whitaker: They ended up paying, what, over $200 billion? Mike Moore: $250 billion, yeah. Bill Whitaker: So when you look back on what you did what has been the impact? Case: 1:17-md-02804-DAP Doc #: 1225-3 Filed: 01/04/19 6 of 9. PageID #: 29677 Mike Moore: We reduced smoking rates to a place that nobody ever thought was possible. So the number one cause of death in America has been reduced dramatically. That's pretty powerful. "The distributors are saying things like, 'We're just truck drivers. We didn't know where the pills went.' Of course, they did" Now, going after the opioid industry, Mike Moore is using the same playbook he used against tobacco and more recently against BP for the Gulf Oil Spill: build legal and public pressure until the companies see no choice but to settle, and fork over billions. Mike Moore: Here's the deal. There's a huge pill spill in this country. It's huge. Bill Whitaker: Pill spill? Mike Moore: Pill spill. Huge pill spill. It never should've occurred. Everybody's got some fault. But we have 72,000 people dying every year. Let's figure out a way to resolve this thing. You guys made billions of dollars off of this. Take some of that money and apply it to the problem that you helped cause. He's a long way from convincing the drug industry to do that, of course, that's why all the lawsuits. The first targets are opioid manufacturers like Purdue Pharma, which makes oxycontin, the pill that fueled the opioid epidemic. Mike Moore: Purdue Pharma created an environment so that opioid use was okay. So if you prescribe your patients this drug, there's less than 1 percent chance they'll get addicted. That was a lie, a big lie. Bill Whitaker: Can you prove that in court? Mike Moore: Absolutely. The lawyer who made BP pay The lawyer who made BP pay Purdue Pharma declined our request for an interview, but said in a statement that when the FDA approved oxycontin in 1995 it authorized the company to state on the label that "addiction to opioids legitimately used is very rare." But as evidence of abuse mounted, the company admitted in federal court in 2007 that it had misled doctors and consumers about just how addictive oxycontin can be. Mike Moore: The Purdue Pharma case is an easy case. I hate to say it, but it's an easy case to prove. You can prove that they told the lies that they told. Case: 1:17-md-02804-DAP Doc #: 1225-3 Filed: 01/04/19 7 of 9. PageID #: 29678 It has been considered tougher to build a case against Mike Moore's other targets, the huge drug distributors who've made billions delivering opioids from manufacturers to pharmacies. Mike Moore: The distributors are saying things like, "We're just truck drivers. We didn't know where the pills went." Of course, they did. There's a Controlled Substance Act. Controlled Substance Act. You're supposed to control these pills. And when you don't, you have a responsibility for it. It-- it's real simple. "The stories that you've heard from some of the DEA investigative agents concerning the large volumes of pills going into certain parts of our country are absolutely true." It's also simple why Moore is going after the biggest players in drug distribution: because they have much deeper pockets than the manufacturers. Purdue Pharma, for example, had less than $2 billion in revenue last year. Distributor McKesson, by contrast, had $208 billion in revenue. Mike Moore: McKesson, you're the sixth largest company in this country. You're telling the American public you didn't have systems in place to adhere to the Controlled Substance Act? Seriously? Mike Moore and his allies now have what they characterize as devastating evidence proving that distributors knew what they were doing. A huge confidential DEA database called ARCOS tracks all transactions involving controlled substances. This spring, a federal judge in Cleveland who is hearing many of the local lawsuits ordered all that data to be handed over to the plaintiffs' lawyers. Burton LeBlanc Burton LeBlanc: And I can actually tell you which distributor distributed to which particular pharmacy, by year, by volume, and where the pills came from. Burton LeBlanc is a Louisiana lawyer who regularly huddles with Mike Moore in Grayton Beach. His firm represents hundreds of cities and counties in their opioid lawsuits, and his team has taken the lead in analyzing the ARCOS data. Burton LeBlanc: In terms of the wholesale distributor's duty to report suspicious orders, we can immediately look at volume and detect patterns with the data that we currently have. Bill Whitaker: So, you can see that for every pharmacy in the-- in the country? Burton LeBlanc: I have it for every transaction in the United States. Case: 1:17-md-02804-DAP Doc #: 1225-3 Filed: 01/04/19 8 of 9. PageID #: 29679 Bill Whitaker: What's the most important thing that it has shown you? Burton LeBlanc: That the stories that you've heard from some of the DEA investigative agents concerning the large volumes of pills going into certain parts of our country are absolutely true. One of those stories concerned Kermit, West Virginia, a town of just 400 people, where nine million opioid pills were delivered in just two years to a single pharmacy. Bill Whitaker: Did the companies have access to this information? Burton LeBlanc: It was their data. That data has now been shared with state attorneys general, including Ohio's Mike DeWine. Attorney General Mike DeWine: I'm not allowed to talk about the specifics. But I will simply tell you it's shocking. Anyone who was looking at those numbers, as those middlemen were, as these distributors were, clearly, clearly should've seen that something was dramatically wrong. "If they cared enough, maybe we would not have lost 500,000 lives from this problem." Like Purdue, drug distributors declined our request for an interview, but in a statement from their trade association, said, "it defies common sense to single out distributors for the opioid crisis… distributors deliver medicines prescribed by a licensed physician and ordered by a licensed pharmacy." But Mike Moore insists that does not let the companies off the legal hook. Mike Moore: If you've got walking around sense and you care, you're gonna check before you send nine million pills to a little, bitty county in West Virginia or Mississippi or Louisiana or Ohio. You're gonna check if you care. Bill Whitaker: You think they don't care? Mike Moore: I don't think they cared enough. And if they cared enough, maybe we would not have lost 500,000 lives from this problem. It's-- it just-- it appalls me. Trial dates have been set for next year in a few of the state and local cases. But rather than go to trial, and just as he did with tobacco, Mike Moore hopes to force a mega-settlement to fund drug treatment, prevention, and education. Bill Whitaker: You had to have thought about how much money you would need to do the projects that you foresee? Mike Moore: Oh, I've seen all the models. To be effective, we need at least $100 billion to start off with. Bill Whitaker:  And I know you've heard the criticism, that with all these lawyers involved, that this is just a bunch of trial lawyers looking for a great, big payday. Mike Moore: Right. I don't care one whit about any money in this case. Not one whit whatsoever about it. Bill Whitaker: Nobody's gonna believe that the attorneys are not going to make any money. Mike Moore: No, no, no. No, no, and I'm not saying that. I was talking about-- all I can speak for is me. Bill Whitaker: You made money off tobacco. Mike Moore: Nope, not a penny. That's because for all the years of the tobacco litigation, and many years after, Moore was working for a modest state salary as Mississippi attorney general. Case: 1:17-md-02804-DAP Doc #: 1225-3 Filed: 01/04/19 9 of 9. PageID #: 29680 Bill Whitaker: You made money off of BP spill. Mike Moore: I made some money on helping resolve the case, yeah. Moore has made enough money to be comfortable. At age 66, this may be his last big case, and he believes the ARCOS data gives him the ammunition he needs to demolish the opioid industry's argument that it should not be blamed. Mike Moore: Nobody in the world's gonna believe that. And-- and don't go try to tell that to 12 jurors in Mississippi or Ohio who've lost people from this. You know what-- (LAUGH) you know what those jurors are gonna do? They're gonna go in the back room, they're gonna spend about 30 minutes thinking about it, gonna come back out and bam. Produced by Rome Hartman. Associate producer, Sara Kuzmarov. © 2018 CBS Interactive Inc. All Rights Reserved. CBSNews.com CBS Interactive Follow Us Site Map Privacy Policy Facebook Help Contact Us Ad Choice Terms of Use Twitter RSS CBS Bios Careers Mobile User Agreement About CBS Email Newsletters YouTube CBSi Careers Internships Development Programs Advertise Closed Captioning CBS News Store CBS News Radio CBS Local Copyright © 2019 CBS Interactive Inc. All rights reserved. Search... Case: Doc 1225-4 Filed: 01/04/19 1 of 3. PagelD 29681 Exhibit 2 Case: 1:17-md-02804-DAP Doc #: 1225-4 Filed: 01/04/19 2 of 3. PageID #: 29682 Three Bryant Park 1095 Avenue of the Americas New York, NY 10036-6797 +1 212 698 3500 Main +1 212 698 3599 Fax www.dechert.com MARK CHEFFO December 16, 2018 mark.cheffo@dechert.com +1 212 698 3814 Direct +1 212 698 3599 Fax VIA E-MAIL Attorney General Mike DeWine c/o Mark H. Troutman, Esq. Isaac Wiles Burkholder & Teetor, LLC Two Miranova Place, Suite 700 Columbus, OH 43215-5098 mtroutman@isaacwiles.com Mike Moore, Esq. Mike Moore Law Firm, LLC P.O. Box 321048 Flowood, MS 39232 mm@mikemoorelawfirm.com Re: In re National Prescription Opiate Litigation, Case No. 1:17-MD-2804 Dear Gentlemen: I am writing on behalf of certain manufacturer defendants in the In Re Opiate Litigation pending before Judge Polster in Cleveland. We understand that Mr. DeWine and Mr. Moore will be featured in a segment scheduled to air tonight on 60 Minutes regarding the opioid crisis. Of course, we have not seen the segment, nor do we have the full transcript or context. But, we have seen the “teaser” for the segment, and it has raised some significant concerns and questions. First, based on the limited, and admittedly incomplete information, we have seen, we are concerned that statements provided to 60 Minutes may violate the letter and/or spirit of Judge Polster’s protective order regarding ARCOS data. Second, we are concerned that statements made to 60 Minutes may violate certain provisions of Ohio’s laws and ethical provisions, including, but not limited to, Ohio’s “Trial Publicity” ethics rules. As noted, because we do not have complete information, and do not yet know what was provided, or what will air, we can’t be more specific and it’s not clear what, if any, violations occurred. However, since Mr. DeWine and Mr. Moore know what was given or stated to 60 Case: 1:17-md-02804-DAP Doc #: 1225-4 Filed: 01/04/19 3 of 3. PageID #: 29683 Attorney General Mike DeWine c/o Mark H. Troutman, Esq. Mike Moore, Esq. December 16, 2018 Page 2 Minutes, we are providing this notice in advance of the airing to allow you the opportunity to take appropriate action to prevent or remediate any violations of law or the protective order, to the extent that they occurred, before the segment airs and potentially causes significant and irreparable harm to one or more defendants. As you can understand, defendants reserve our rights concerning this matter until after we have a chance to review what ultimately airs on the segment. Thank you both for your attention to this important matter. Please feel free to contact me if you have any questions. Sincerely, Mark S. Cheffo Mark S. Cheffo Case: 1:17-md-02804-DAP Doc #: 1225-5 Filed: 01/04/19 1 of 1. PageID #: 29684 UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF OHIO EASTERN DIVISION MDL No. 2804 IN RE: NATIONAL PRESCRIPTION OPIATE LITIGATION Case No. 1:17-md-2804 THIS DOCUMENT RELATES TO: ALL CASES Hon. Dan Aaron Polster ORDER GRANTING CERTAIN DEFENDANTS’ MOTION FOR LEAVE TO FILE MOTION FOR RELIEF CONCERNING IMPROPER EXTRAJUDICIAL STATEMENTS AND VIOLATIONS OF COURT ORDERS This matter having come before the Court upon Certain Defendants’ motion for leave to file their Motion for Relief Concerning Improper Extrajudicial Statements and Violations of Court Orders; the Court having reviewed the motion and related papers; due and proper notice of the motion having been provided; and after due deliberation and sufficient cause appearing therefore, the Court finds that the motion should be GRANTED. SO ORDERED this ___ day of _________, 2019. ________________________________ HON. DAN AARON POLSTER UNITED STATES DISTRICT JUDGE 1